Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
Abbreviated Title:  Anakinra in pustular  dermatoses   
CC Protocol #: 13-AR-0071  M 
Version Date:   December 12 , 2018  
NCT#: [STUDY_ID_REMOVED]  
Title: A phase 2 study of anakinra in inflammatory  pustular dermatoses: Evaluation of 
therapeutic efficacy and valid ation of pathogenic mechanisms  
NIH Principal Investigator:  Edward W. Cowen , M.D. , M.H.S c. 
Acting Chief , Dermatology Branch   
Senior Clinician and Head , Dermatology Consultation Service  
National Institute of Arthritis and Musculoskeletal and Skin  
Diseases (N IAMS)  
10 Center Drive, Room 12N240A  
Bethesda, MD 20892  
Phone 301 -480-7196  
cowene@mail.nih.gov   
 
PARTICIPATING SITE  
Institutional PI:  Haley Naik, M.D.   
Institution:  University of California San Francisco  
Instituti on FWA#:  FWA 00000068  
Address:  1701 Divisadero Street, Third Floor,  
 San Francisco, CA 94143  
Phone Number:  781-367-5876  
Email:  Haley.Naik@ucsf.edu  
 
Commercial Agent :    Anakinra/Kineret®  
2 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 PRÉCIS  
Background:  
• Inflammatory disorders that present with neutrophilic pustular skin lesions, including 
generalized pustular psoriasis, are characterized by severe cutaneous manifestations, 
generalized inflammation and significant morbidity.  
• Recent studies in patients with phenotypically similar pustular diseases have identified 
two monogenic forms of neutrophilic pustular psoriasis implicating interleukin ( IL)-1 in 
disease pathogenesis.  
o Deficiency of the IL -1 receptor antagonist ( IL1RN , DIRA)  is an autosomal 
recessive condi tion characterized by severe generalized pustular eruption s in the 
neonatal period, osteopenia, lytic bone lesions, joint pain, respiratory 
insufficiency, thrombosis, elevated acute phase reactants and significant 
mortality . Patients with this condition ha ve responded rapidly to IL -1 receptor 
antagonist, anakinra.  
o Deficiency of IL -36 receptor antagonist ( IL-36RN /IL1F5 , DITRA) is an 
autosomal recessive  condition with episodic widespread pustular skin lesions, 
fevers and systemic inflammation defined by marke d leukocytosis and elevated c -
reactive protein .  
• Both IL1RN  and IL36RN/IL1F5 are highly expressed in epidermal keratinocytes, 
suggesting a role for keratinocytes in initiating innate immunity -mediated inflammatory 
skin diseases, and ultimately manifesting in a pustular phenotype.   
• Patients with inflammatory pustular diseases often respond poorly to conventional 
treatment with methotrexate, cyclosporine and anti -TNF agents . 
• Two recent case reports describe patients with pustular psoriasis unresponsive to TNF  
inhibition who responded to anti -IL-1 receptor therapy with anakinra . 
• We hypothesize that monogenic and polygenic inflammatory pustular skin diseases share 
common pathogeni c mechanisms mediated by IL -1. 
• We propose a phase 2 study  that will utilize a colla borative bench -to-bedside approach, 
applying targeted anti -IL-1 therapy , novel imaging modalities , and laboratory techniques 
including immunohistochemistry , gene expression and cytokine studies, and in vitro  
manipulations of skin  to dissect and validate pa thways in these complex diseases.  
Objective:  
• To characterize the clinical efficacy, optimal dosing  and safety of anakinra in patients 
with pustular dermatoses.  
Eligibility:  
• Age ≥ 18 years.  
• Active macroscopic noninfectious pustular skin lesions involving ≥ 5% of the total body 
surface area , or palmoplantar involvement.   
• Histopatholo gic confirmation of epidermal neutrophilic pustul osis. 
• Patients must have maintained a stable dose of immunosuppressant  therapy , retinoids or 
anti-neutrophil therapy  for 2 weeks  prior to study initiation with resultant stable or 
worsening skin disease.  
3 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 • Use of biologic agents requires a washout period of at least 3 half -lives prior to study 
initiation.  
• Patients must have organ and marrow function as defined below:  
 leukocytes       >3,000/mcL  
 absolute neutrophil count   >1,500/mcL  
 platelets        >100,000/mcL  
 creatinine       within normal institutional limits  
 OR 
 creatinine clearance     >60 mL/min/1.73 m2 for patients with 
creatinine levels above institutional normal.  
Design:  
• A 16-week, open -label  phase 2 study . 
• Patients will initially receive treatment with anakinra 1 00 mg/day by self-administered 
subcutaneous inject ion.  
• Disease response will be assessed every 4 weeks, and determination of dose escalation 
will be made based on clin ical assessment. Dose escalation can increase up to 200 
mg/day , and for patients >75  kg up to 300  mg/day at the end of week 8.  
• If a response  is achieved with anakinra, other immunosuppressants administered for the 
purpose of treatment of pustular skin dise ase may be tapered per physician discretion.  
• Clinical assessment, and laboratory and subjective data will be collected in-person every 
4 weeks to determine disease response . Telephone assessments will be performed 
weekly.  
• Twenty -five evaluable patients wi ll be enrolled onto this trial. The accrual ceiling for this 
study will be set to 30. 
 
4 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 TABLE OF CONTENTS  
PRÉCIS  ................................ ................................ ................................ ................................ ...........  2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  4 
1 INTRODUCTION  ................................ ................................ ................................ ..................  8 
1.1 Study Objectives  ................................ ................................ ................................ ..............  8 
1.1.1  Primary Objective  ................................ ................................ ................................ ..... 8 
1.1.2  Secondary Objectives ................................ ................................ ................................  8 
1.2 Background and Rationale  ................................ ................................ ...............................  8 
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  ................................ .......................  13 
2.1 Eligibility Criteria  ................................ ................................ ................................ ..........  13 
2.1.1  Inclusion Criteria  ................................ ................................ ................................ .... 13 
2.1.2  Exclusion Criteria  ................................ ................................ ................................ ... 14 
2.1.3  Recruitment Strategies  ................................ ................................ ............................  15 
2.2 Screening Evaluation ................................ ................................ ................................ ...... 16 
2.3 Registration Procedures ................................ ................................ ................................ .. 16 
2.3.1  Registration at the  Clinical Center  ................................ ................................ ..........  16 
2.3.2  For Participating Site Registration  ................................ ................................ ..........  16 
2.3.3  Treatment Assignment and Randomization/ Stratification Procedures  ..................  17 
2.4 Baseline Evaluation  ................................ ................................ ................................ ........  17 
3 STUDY IMPLEMENTATION  ................................ ................................ ............................  19 
3.1 Study Design  ................................ ................................ ................................ ..................  19 
3.1.1  Dose Limiting Toxicity  ................................ ................................ ...........................  20 
3.1.2  Dose Escalation  ................................ ................................ ................................ ....... 20 
3.2 Drug Administration  ................................ ................................ ................................ ...... 21 
3.3 Dose Modifications  ................................ ................................ ................................ ........  22 
3.4 Quality of life tools/questionnaires  ................................ ................................ ................  24 
3.5 Study Flowchart  ................................ ................................ ................................ .............  26 
3.6 Study Calendar  ................................ ................................ ................................ ...............  28 
3.7 Surgical Guidelines  ................................ ................................ ................................ ........  32 
3.8 Ophthalmologic Procedures  ................................ ................................ ...........................  32 
3.8.1  Ophthalmic Examination with Dilation  ................................ ................................ .. 32 
5 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3.8.2  Fluor escein Angiography (if clinically indicated)  ................................ ..................  32 
3.8.3  Optical Coherence Tomography (OCT)  ................................ ................................ . 32 
3.8.4  Microperimetry  ................................ ................................ ................................ ....... 32 
3.9 Criteria for Removal from Protocol Therapy and Off Study Criteria  ............................  33 
3.9.1  Criteria for removal from protocol therapy  ................................ ............................  33 
3.9.2  Off-Study Criteria  ................................ ................................ ................................ ... 33 
3.9.3  Off Protocol Therapy and Off Study Procedure  ................................ .....................  33 
3.10  Basic and Clinical Science Research Plan  ................................ ................................ ..... 33 
3.10.1  Characterize and dissect inflammatory pathways in participant lesional skin and 
peripheral blood mononuclear cells  ................................ ................................ ......................  33 
3.10.2  Evaluate systemic inflammation in participants with pustular dermatoses using 
imaging modalities and biomarkers of cardiometabolic disease  ................................ ..........  34 
3.10.3  Evaluate keratinocyte responses to targeted inflammatory stimuli including 
infectious agents and danger molecules.  ................................ ................................ ...............  35 
4 CONCOMITANT MEDICATIONS/MEASURES  ................................ ..............................  36 
4.1 Supportive Care  ................................ ................................ ................................ ..............  36 
4.1.1  NIH Patients  ................................ ................................ ................................ ............  36 
4.1.2  UCSF Patients  ................................ ................................ ................................ .........  36 
5 BIOSPECIMEN COLLECTION  ................................ ................................ ..........................  37 
5.1 Correlative studies for r esearch  ................................ ................................ ......................  37 
5.1.1  Blood (Clinical and Research Samples)  ................................ ................................ . 37 
5.1.2  Research samples collected at UCSF  ................................ ................................ ...... 37 
5.2 Sample Storage, Tracking and Disposition  ................................ ................................ .... 37 
6 DATA CO LLECTION AND EVALUATION  ................................ ................................ ..... 38 
6.1 Data Collection  ................................ ................................ ................................ ...............  38 
6.2 Response Criteria  ................................ ................................ ................................ ...........  39 
6.2.1  Definitions ................................ ................................ ................................ ...............  39 
6.2.2  Disease Parameters  ................................ ................................ ................................ . 40 
6.2.3  Methods for Evaluation of Measurable Disease  ................................ .....................  40 
6.2.4  Response Criteria  ................................ ................................ ................................ .... 40 
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
 41 
7.1 Definitions  ................................ ................................ ................................ ......................  41 
6 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 7.1.1  Adverse Event  ................................ ................................ ................................ .........  41 
7.1.2  Suspected adverse reaction  ................................ ................................ .....................  41 
7.1.3  Unexpected adverse reaction  ................................ ................................ ..................  41 
7.1.4  Serious ................................ ................................ ................................ .....................  41 
7.1.5  Serious Adverse Event  ................................ ................................ ............................  41 
7.1.6  Disability  ................................ ................................ ................................ .................  42 
7.1.7  Life-threatening adverse drug experience  ................................ ...............................  42 
7.1.8  Protocol Deviation (NIH Definition)  ................................ ................................ ...... 42 
7.1.9  Non-compliance  (NIH Definition)  ................................ ................................ ..........  42 
7.1.10  Unanticipated Problem ................................ ................................ ............................  42 
7.2 NIH Intramural  IRB and Clinical Director Reporting  ................................ ...................  42 
7.2.1  NIH Intramural IRB and NCI CD Expedited Reporting of Unanticipated Problems 
and Dea ths ................................ ................................ ................................ .............................  42 
7.2.2  NIH Intramural IRB Requirements for PI Reporting at Continuing Review  .........  43 
7.3 NCI Guidance for Reporting Expedited Adverse Events for Multi -Center Trials  .........  43 
7.4 Data and Safety Monitoring Plan  ................................ ................................ ...................  43 
7.4.1  Principal Investigator/Research Team  ................................ ................................ .... 43 
7.4.2  Safet y Monitoring Committee (SMC)  ................................ ................................ .... 44 
8 STATISTICAL CONSIDERATIONS ................................ ................................ ..................  44 
9 COLLABORATIVE AGREEMENTS  ................................ ................................ .................  44 
9.1 Agreement Type  ................................ ................................ ................................ .............  44 
9.1.1  Clinical Trials Agreement  ................................ ................................ .......................  44 
9.1.2  Material Transfer Agreement  ................................ ................................ ..................  44 
9.2 Multi -Institutional Guidelines  ................................ ................................ ........................  44 
9.2.1  IRB Approvals  ................................ ................................ ................................ ........  44 
9.2.2  Amendments and Consents  ................................ ................................ .....................  45 
10 HUMAN SUBJECTS PROTECTIONS  ................................ ................................ ...............  45 
10.1  Rationale For Subject Selection  ................................ ................................ .....................  45 
10.2  Participation of Children  ................................ ................................ ................................  45 
10.3  Participation of N IH Subjects Unable to Give Consent  ................................ .................  45 
10.3.1  For Participating Sites  ................................ ................................ .............................  45 
10.4  Evaluation of Benefits and Risks/Discomforts  ................................ ..............................  45 
7 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 10.5  Risks/Benefits Analysis ................................ ................................ ................................ .. 46 
10.6  Consent Process and Documentation  ................................ ................................ .............  46 
10.6.1  Telephone Reconsent  ................................ ................................ ..............................  47 
10.6.2  Informed consent of non -English speaking subjects  ................................ ..............  47 
11 PHARMACEUTICAL INFORMATION  ................................ ................................ .............  47 
11.1  Anakinra  ................................ ................................ ................................ .........................  47 
11.1.1  Source: Biovitrum  ................................ ................................ ................................ ... 48 
11.1.2  Toxicity  ................................ ................................ ................................ ...................  48 
11.1.3  Formulation and preparation  ................................ ................................ ...................  50 
11.1.4  Stability an d Storage  ................................ ................................ ...............................  50 
11.1.5  Administration procedures  ................................ ................................ ......................  50 
11.1.6  Incompatibilities  ................................ ................................ ................................ ..... 51 
12 REFERENCES  ................................ ................................ ................................ .....................  52 
13 APPENDIX A : FORBIDDEN DRUGS  ................................ ................................ ...............  56 
14 APPENDIX B: PATIENT D IARY  ................................ ................................ .......................  57 
15 APPENDIX C: PATIENT HANDOUT  ................................ ................................ ...............  58 
16 APPENDIX D: DOSE MODIFICATION FLOW CHART  ................................ .................  59 
17 APPEND IX E: SHORT FORM  36 (ENGLISH AND SPANISH)  ................................ ...... 60 
18 APPENDIX F: DERMATOLOGY LIFE QUALITY (ENGLISH AND SPANISH)  ..........  74 
19 APPENDIX G: DERMATOLOGY LIFE QUALITY SCORING TOOL  ...........................  77 
20 APPENDIX H: PUSTULAR DERMATOSIS CLINICAL ASSESSMENT SCALE  ..........  79 
21 APPENDIX I: HEALTH ASSESSMENT QUESTIONNAIRE ................................ ...........  83 
22 APPE NDIX J: JOINT EXAM CLINICAL ASSESSMENT FORM  ................................ .... 85 
23 APPENDIX K: REVIEW OF SYSTEMS  ................................ ................................ ............  86 
24 APPENDIX L: CCR PROBLEM REPORT FORM  ................................ .............................  88 
 
8 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 1 INTRODUCTION  
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objective  
• To assess the  proportion of participants treated with anakinra who achieve 50% disease 
improvement by the end of  week 12, as measured by total body surface area involvement 
(TBSAI 50). 
1.1.2 Secondary Objectives  
Clinical Objectives  
Labor atory  Objectives  
• To characterize and analyze  inflammatory pathways in skin and peripheral blood 
mononuclear cells using immunohistochemistry, cytokine and gene expression studies.  
• To evaluate systemic inflammation in patients  with pustular dermatoses using  novel imaging 
modalities , and  assess  biomarkers of cardiometabolic disease  using novel techniques 
including nuclear magnetic resonance spectroscopy (NMR) and  HDL cholesterol efflux 
capacity . 
• To evaluate keratinocyte responses to targeted inflammatory stim uli including infectious 
agents and danger molecules.  
 
1.2 BACKGROUND AND RATIONALE  
Inflammatory disorders that present with neutrophilic pustular skin lesions, including generalized 
pustular psoriasis, are characterized by severe cutaneous manifestations, gen eralized 
inflammation and significant morbidity.  Interestingly, several recent studies in patients with 
phenotypically similar pustular diseases have identified two monogenic forms of neutrophilic 
pustular psoriasis implicating interleukin (IL) -1 in disea se pathogenesis  (Table 1).  Whereas 
dysregulated NFkB/TNF and IL -12/23 pathways have an established role in plaque -type 
psoriasis, these recent reports of monogenic pustular diseases have suggested a role for IL -1 in 
the development of pustular skin lesions.  
 
 
 • To assess and characterize associations between inflammatory pustular dermatoses and 
systemic manifestations from ophthalmologic, cardiovascular, gastrointestinal, 
rheumatologic and immunologic perspectiv es. 
• To assess the changes in quality of life  and functional measures  during the course of anakinra 
therapy.   
• To determine adequate dosing and safety and assess toxicity with the use of anakinra in the 
management of inflammatory pustular dermatoses.  
 
9 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 Table 1: Identified m onogenic pustular skin diseases  
 Deficiency of IL -1 Receptor 
Antagonist (DIRA)  Deficiency of IL -36 Receptor 
Antagonist (DITRA)  
Mutation  IL1RN  IL-36RN/IL1F5  
Inhe ritance  Autosomal recessive  Autosomal recessive  
Founder and 
type of 
mutation  Multiple founder deletion mutations 
described in Newfoundland, Puerto 
Rico, Lebanon, Holland and Brazil  1-4. Single founder homozygous mi ssense 
mutation described in 8 Tunisian 
families5.  
Two additional missense mutations 
found in 3 unrelated patients from 
England6. 
Biological 
consequence  Loss of function of IL1RA resulting in 
unopposed I L-1 activity  Decreased IL36RA protein resulting 
in increased inflammatory cytokines 
(ex vivo)  
Clinical 
phenotype  Generalized pustules  
Lytic bone lesions  
Respiratory insufficiency  
Thrombosis  
Elevated acute phase reactants  
Significant mortality  Episodic widespread pustules  
Fevers  
Elevated acute phase reactants  
Treatment  IL-1 receptor antagonist, anakinra  None described^  
^Two patients with pustular psoriasis (but no mutation in IL -36RN) were successfully treated 
with IL -1 blockade7. 
 
Deficiency of the IL -1 receptor antagonist ( IL1RN , DIRA) leads to a severe generalized pustular 
eruption in the neona tal period, osteopenia, lytic bone lesions, joint pain, respiratory 
insufficiency, thrombosis, elevated acute phase reactants and significant mortality  1-4.  Loss of 
function m utations in the IL -36 receptor antagoni st (IL-36RN,  another member of the IL -1 
cytokine family,  also known as IL1F5 ) were recently reported.  These mutations lead to an 
autosomal recessive form of generalized pustular psoriasis called DITRA (deficiency of IL -36 
receptor antagonist), a condition  characterized by episodic widespread pustular skin lesions, 
fevers and systemic inflammation defined by marked leukocytosis and elevated c -reactive 
protein5, 6.  Both DIRA and DITRA are associated with similar histologic findings including 
epide rmal hyperplasia and epidermal and dermal accumulation of neutrophils, T lymphocytes 
and dendritic cells , suggesting a common  underlying pathogenic pathway .  Furthermore, both 
IL1RN  and IL36RN/IL1F5 are highly expressed in epidermal keratinocytes, suggesti ng a role for 
keratinocytes in initiating innate immunity -mediated inflammatory skin diseases8, 9, and 
ultimately manifesting in a pustular phenotype.   
The availability of biologics targeting IL -1 provides us with p otent clinical tools to dissect and 
validate these pathways in inflammatory  pustular skin diseases.  Patients with pustular diseases 
often respond poorly to conventional treatment with systemic retinoids, methotrexate, 
10 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 cyclosporine and anti -TNF agents .  Two recent case reports , however, describe patients with 
generalized pustular psoriasis refractory to TNF inhibition who responded to anti -IL-1 receptor 
antagonist therapy with anakinra7, 10.  However, beyond these ca se reports, the efficacy of IL -1 
inhibition along the spectrum of neutrophilic and pustular skin conditions has not yet been 
systematically explored, and analysis of pathogenesis is lacking.  
In light of these recent case reports and the efficacy of anakin ra in other neutrophilic 
inflammatory diseases such as the periodic fever syndromes, w e hypothesize that monogenic and 
polygenic pustular skin diseases share common pathogenic mechanisms mediated by IL -1.  We 
aim to elucidate the shared inflammatory pathwa ys that contribute to the development of 
neutrophilic pustular diseases.  We propose a phase 2 study that will apply targeted anti -IL-1 
therapy  to dissect and validate the inflammatory pathways important in these complex diseases.  
Published data and our pr eliminary studies provide support for common pathogenic pathways in 
pustular psoriasis.  Keratinocyte dysregulation leads to the production of inflammatory 
chemokines and cytokines, suggesting a role for keratinocytes in  the initiati on of inflammatory 
skin disease11.  DIRA and DITRA  are caused by a mutation in IL-1 family members, IL1RN and 
IL36RN/IL1F5, which are highly expressed in the keratinocytes of the epidermis and suggest an 
important role of the innate immun e system in disease development6.  Activat ed keratinocytes 
recruit neutrophils into the skin, and ultimately manifest in a pustular phenotype.  
Gene expression studies and therapeutic studies support an important contribution of the adaptive  
immun e system in inflammatory diseases.  Published data and preliminary data from our gene 
expression studies suggest that keratinocytes or macrophages carrying CARD14 mutations or 
lacking the IL -36 receptor antagonist produce chemokines IL -8, CCL2 and CCL206.  IL-23 
derived from activated keratinocytes  11 or newly recruited myeloid dendritic cells  12 leads to IL -
17 production.  IL -17 promotes rapid neutrophil recruitment  by inducing the secretion of 
proinflammatory mediators including IL -1, IL -6, IL -8, CXC ligand 1, TNF and GM -CSF, thus 
leading to a cycle of chronic inflammation  13. 
Systemic inflammatory states are also associated with metabolic and cardiovascular risk factors. 
Psoriasis is an example of such  an inflammatory state which has been shown to have an  
association with metabolic and cardiovascular disease.  Experimentally induced  in vivo  
inflammation in healthy humans is associated with robust activation of TNF -α and IL -6 followed 
by a systemic insul in-resistant state, metabolic dyslipidemia and decreased HDL function  14-17.   
Additionally, acute inflammation  is associated with mildly reduced HDL levels and increased 
triglycerides and small dense LDL particles 14, 18.  These lipoprotein responses may be designed 
to prevent cholesterol loss at a time of high cell turnover.  However, sustained dyslipidemia due 
to chronic inflammation may be an important pro -atherogenic feat ure of systemic inflammatory 
conditions.   The lipoprotein pattern observed in conditions like psoriasis (low HDL, reduced apo 
A-I) may be associated with reduction of macrophage cholesterol efflux and blunting of reverse 
cholesterol transport19, an important anti -atherosclerotic pathway in vivo , recently shown to be 
associated with subclinical atherosclerosis and angiographic coronary artery disease 20.  The 
effect of inflamma tion-mediated macrophage efflux defects  is poorly defined in inflammatory  
pustular diseases and may provide additional information about cardiovascular and metabolic 
disease s in systemic neutrophilic inflammatory states.  
One innovative method to investigat e the systemic inflammatory burden is with [18F] -
fluorodeoxyglucose (FDG ) positron emission tomography /computed tomography (PET/CT).  
11 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 FDG -PET/CT is a validated imaging technique that enables measurements of inflammation in 
vivo21.  FDG uptake in the arterial walls reflects metabolic activity of inflammatory cells, 
particularly macrophages, involved in atherosclerotic lesions  22.  A recent study revealed that 
psoriasis is assoc iated not only with clinically observed inflammation in the skin, but also foci of 
subclinical inflammation within the liver, joints, tendons, and aorta that were not explained by 
traditional cardiovascular risk factors or co -morbidities23.  Importantly, vascular inflammation 
detected by PET/CT represents a stable, reproducible phenotype over time in control settings24.  
This modality can aid in detection of vascular inflammat ion, and has high inter -and intra -reader 
reliability24.  Since vascular inflammation on FDG -PET/CT strongly predicted future major 
vascular events and responded to interventions for traditional CV risk factors  25-29, it may also 
serve as a useful marker for evaluating vascular inflammation, disease risk and disease response 
to therapy in a range of inflammatory conditions.  
Chronic inflamma tory states have  also been associated  with development and progression  of 
malignancy .  Notably, IL-1 is found in abundance at tumor sites and thought to play a role in 
carcinogenesis and  tumor growth.  IL-1 inhibition  by IL -1ra may reduc e tumor invasiveness , 
pointing to the potential role of IL-1 inhibition in cancer  therapy30, 31.  Although  monoclonal 
gammopathies have been anecdotally associated with generalized pustular dermatoses32, 33, the 
association betwee n inflammatory pustular dermatoses and malignancy has not been 
systematically studied and this study may pr ovide further insights into the relationship between 
innate immunity  and neoplastic disease.  
In this study, we intend to apply recent insights gaine d from  monogenic disorders  to understand 
the pathogenesis of neutrophilic pustular skin disorders.  We will utilize a fully collaborative 
bench -to-bedside approach, including targeted therapeutic intervention  with anakinra  and 
powerful and novel clinical a nd laboratory techniques including  immunohistochemistry , gene 
expression analysis, in vitro manipulations of skin  cells, and FDG PET CT  to dissect these 
complex diseases.  
Anakinra is an IL-1 receptor 1 (IL -1R1) antagonist which competitive ly blocks the act ivity of IL -
1.  This agent  was initially evaluated in sepsis patients , but is currently FDA approved for 
rheumatoid arthritis (RA)34-36. It is indicated for the management of signs and symptoms of 
moderately to seve rely active rheumatoid arthritis in patients 18 years of age or older who have 
failed 1 or more disease modifying antirheumatic drugs (DMARDs) .  Anakinra has been 
evaluated in over 1400 RA patients in four randomized, double -blind, placebo -controlled trial s37-
42.  It is also effective  in the management of monogenic autoinflammatory diseases including  
neonatal -onset multisystem inflammatory disease  (NOMID )43-45, as well as mono genic diseases 
with a pustular phenotype includ ing DIRA1.   
The most common adverse event associated with anakinra is injection site reaction , which  occur s 
in approximately  71% of patients  and generally  diminish es after 4 -6 weeks of daily use.   The 
most serious  adverse eve nts associated with anakinra  include neutropenia, thrombocytopenia and 
infection.  In placebo -controlled trials, 0.4% of patients treated with anakinra monotherapy  
developed neutropenia.  Two percen t of patients concurrently treated with anakinra and the anti-
TNF agent etanercept developed neutropenia.  Two percent of anakinra patients receiving 
anakinra alone developed a decrease d platelet  count  (WHO toxicity grade 1) as compared with 
0% of patients  treated with placebo.  In placebo -controlled trials in RA patients, the incidence of 
infection was 39%  versus  37% in patients receiving anakinra versus  placebo , respectively .  The 
12 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 incidence of serious infections was 2% versus  1% in patients treated with a nakinra versus  
placebo, respectively.  Serious infection s consisted of bacterial cellulitis, pneumonia, and bone 
and joint infections .  In patients receiving anakinra and etanercept concurrently for up  to 24 
weeks, serious infections were n oted in 7% of pa tients, consist ing primarily of bacterial 
pneumonia and cellulitis42.  Although o pportunistic infections were not observed in randomized, 
double -blind, placebo -controlled clinical trials, one case each of atypical mycobacterial 
infection, histoplasmosis and esophageal candidiasis were observed in an open -label extension 
study of 1346 RA patients40.    
Among 5300 RA patients treated with anakinra in clinical trials for a mean of 15 months, 8 
lymphomas were observed46.  This rate is similar to the  rate expected for the RA patient 
population in which  the rate  of lymphoma  is at least doubled47, 48.  The most common other 
malignancies  observed  in clinical trials were breast, respiratory system, and digestive sy stem  
malignancies .  Four cases  of melanoma were observed in one study and its long -term open -label 
extension, but none of the cases were attributed  to anakinra40.  The significance of the se finding s 
is unclear  and the role of IL -1 antagonists  in the development of malignancy is not known.  
Patients with pustular psoriasis tend to respond poorly to anti -TNF agents and  are typically 
excluded from clinical studies evaluating anti -TNF agents for psoriasis.  Infectious, ne oplastic 
and cardiac complications are associated with anti-TNF therapy .  In 2002, the BIOBADASER 
(Base de Datos de Productos Biologicos de la Sociedad Espanola de Reumatologia ) database 
reported 17 cases of tuberculosis  among  1355 patients treated with in fliximab .  Eleven  patients  
(65%) manifested  extrapulmonary involvement and 2 deaths  occurred  (12% mortality rate), as 
compared with an expected 15% rate of extrapulmonary TB amongst patients with T B and 4.6% 
mortality in the general U.S. population at that  time49.  Serious bacterial and fungal opportunistic 
infections have also been reported in patients treated with anti -TNF agents50.  An increased risk 
of worsening congestive heart failure (CHF) has been demonstrated  with high -dose infliximab 
(all-cause mor tality or CHF hospitalization : 16% at  week 14, 26% at week 28 )51.  Adverse 
cardiac outcomes in patients with CHF are thought to be a class effect with anti -TNF agents.  
Data from the National Databank for Rheumatic Diseases also suggests a modest increase in 
lymphoma with TNF -blockers, with an  incidence ratio of 2.6 (95% CI: 1.4 -4.5) in patients 
treated with infliximab, 3.8  (95% CI: 1.9 -7.5) in patients treated with etanercept and 1.9 (95% 
CI: 1.3 -2.7) in the  patient  population overall52.  Demyelinating disorders, liver toxicity and drug-
induced systemic lupus erythematosus have also been described in association with anti -TNF 
agents53, 5 4.   
Anakinra use for this study is exempt from an investigational new drug (IND) application  
because  this investigation:  
1) Is not intended to be reported to the FDA as a well -controlled study in support of a new 
indication for use of the drug product , nor intended to be used to support any other 
significant change in the labeling for the drug;  
2) Is not intended to support a significant change in advertising to an existing lawfully marketed 
prescription drug product ; 
3) Does not involve a route of administration or dosage level or use in a patient population or 
other factor that significantly increases the risks (or decreases the acceptability of the risks) 
associated with the use of the drug product ; 
13 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 4) Will be conducted in compliance with the requirements for insti tutional review set forth in 
FDA regulations 21 CFR 56, and requirements for informed consent as set forth in FDA 
regulations 21 CFR 50.  
2 ELIGIBILITY ASSESSME NT AND ENROLLMENT   
2.1 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria  
2.1.1.1  Females and males, a ged ≥18.   
2.1.1.2  Patients  must demonstrate active noninfectious  inflammatory pustular skin lesions 
resembling pustular psoriasis and involving ≥ 5% total body surface area , or 
palmoplantar involvement .  Conditions may include, but are not be limited to, pustular 
psoriasis, Sneddon -Wilkinson disease, subcorneal pustular dermatosis, reactive arthritis, 
palmoplantar pustulosis , acrodermatitis continua of Hallopeau  and palmoplantar 
pustular psoriasis . 
2.1.1.3  Patients must have histopathologic confirmation of epidermal neutroph ilic pustular skin 
disease . 
2.1.1.4  If taking immunosuppressants, retinoids or anti -neutrophil therapy, participants must 
maintain  stable dose s of these medications during the  2 weeks prior to study initiation .  
2.1.1.5  Patients must have stable topical medication regimen  for 2 weeks prior to study initiation  
2.1.1.6  Patients must have normal organ and marrow function as defined below:   
 leukocytes       >3,000/mcL  
 absolute neutrophil count   >1,500/mcL  
 platelets        >100,000/mcL  
 creatinine       within normal institutional limits  
 OR 
 creatinine clearance     >60 mL/min/1.73 m2 for patients with 
creatinine levels above institutional normal.  
 
2.1.1.7  Quantiferon TB Gold must be performed for screening for mycobacterium tuberculosis 
infection. However, a tuberculin skin test may be placed if t he Quantiferon TB gold test 
is indeterminate (see below). Patients must have a negative Quantiferon TB Gold (or 
tuberculin skin test) or evidence of appropriate treatment prior to study entry (see 
below).  
Negative Quantiferon TB gold  Begin study  
Indeterm inate Quantiferon TB gold  Place tuberculin skin test  (TST) . If 
negative, begin study.  
Positive Quantiferon TB gold or TST Negative CXR and ≥ 1month Tx 
prior to 1st dose of study drug  
 
14 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 2.1.1.8  Patient s must be able to understand and sign a written informed consent document and 
complete study -related procedures and questionnaires.  
2.1.2 Exclusion Criteria  
2.1.2.1  Enrollment in any other investigational treatment study or use of an investigational agent, 
or has not yet completed at least 3 half-lives  since ending another investigational device 
or drug trial.  
2.1.2.2  History of treatment with canakinumab within the 12 months prior to study initiation.  
2.1.2.3  History of anakinra use. 
2.1.2.4  History of  phototherapy within 2 weeks prior to study initiation.  
2.1.2.5  Patients may NOT concurrently be on biologic therapy such as etanercept, adalimumab, 
alefacept, infliximab, ritux imab or rilonacept (APPENDIX A: FORBIDDEN 
DRUGS ). If there is a history of use of biologic agents, there must be a washout period 
of at least 3 half -lives prior to study initiation.  
2.1.2.6  Subjects who experience a  significant flare after discontinuation of a TNF inhibitor as 
part of this stud y that requires urgent medical management or hospitalization, or in the 
estimation of the principal investigator poses excessive risk to the patient to enter the 
study . 
2.1.2.7  Other defined dermatologic conditions which may include pustules as part of the clinica l 
presentation, but which clinically and/or histologically do not resemble pustular 
psoriasis. Examples include, but are not limited to acute generalized exanthematou s 
pustulosis  (AGEP , a drug -induced pustular dermatosis typically caused by beta -lactam 
antibiotics, tetracyclines, oral antifungals and other drugs ), bacterial or fungal 
folliculitis, cutaneous candidiasis, tinea pedis, tinea corporis, neutrophilic eccrine 
hidradenitis or eosinophilic pustular folliculitis (Ofuji syndrome).  
2.1.2.8  Known diagnosis of D IRA.  
2.1.2.9  History of allergic reactions attributed to compounds of similar chemical or biologic 
composition to  anakinra or other agents used in study.   Known hypersensitivity to 
CHO -cell derived biologics or any components of anakinra.  
2.1.2.10  Treatment with a live vi rus vaccine during the 3 months prior to baseline visit.   No live 
vaccines will be allowed throughout the course of this study.  
2.1.2.11  Patients with a ctive or untreated malignancy -- with the exception of cutaneous basal or 
squamous cell carcinomas,  or in situ ce rvical carcinoma -- are ineligible because of the 
immunomo dulating effects of anakinra .  The risk of recurrent malignancy secondary to 
this drug is unknown.  
2.1.2.12  Presence of active infection .  History of exposure to TB (positive PPD  or Quantiferon 
TB gold ) who h ave not been treated with a TB prophylaxis regimen for at least one 
month.  
2.1.2.13  Chest x -ray (if Quantiferon TB Gold is positive) demonstrating  pleural scarring and/or 
calcified granuloma consistent with prior or current untreated TB.  
2.1.2.14  History of  chronic or rec urrent infection including but not limited to HIV, hepatitis B or 
hepatitis C.    
15 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 2.1.2.15  Individuals with severe  or uncontrolled recurrent cutaneous infections who are 
considered at elevated risk for serious infection on  anakinra therapy will be excluded 
per physi cian discretion.  
2.1.2.16  Presence of other known significant autoimmune or inflammatory disease.  Examples 
include major chronic infectious/inflammatory/immunologic disease s such as systemic 
lupus erythematosus , rheumatoid arthritis, Sjogren’s syndrome and periodi c fever 
syndromes .  
2.1.2.17  Other immunoregulatory or immunodeficiency disease s, such as multiple sclerosis.  
2.1.2.18  Individuals with life -threatening or disabling inflammation of the eyes , gut or joints 
requiring urgent or immediate medical attention , or at the  physician ’s discretion . 
2.1.2.19  Subjects for whom there is concern about compliance with the protocol procedures.  
2.1.2.20  Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, uncontrolled or unmonitored psychiatric illness/social situation s, or history of 
congestive heart failure, unstable angina pectoris  or medically significant cardiac 
arrhythmia that would limit compliance with study requirements.  
2.1.2.21  Presence of other severe acute or chronic medical or psychiatric condition, or 
significant  laboratory abnormality requiring further investigation that may cause undue 
risk for the subject’s safety, inhibit protocol participation, or interfere with 
interpretation of study results, and in the judgment of the investigator would make the 
subject enrollment inappropriate.  
2.1.2.22  The effects of anakinra  on the developing human fetus are unknown.  Women of child -
bearing potential and men must agree to use adequate contraception (hormonal or 
barrier method of birth control or abstinence) prior to study entry and for the duration of 
study participation.  Should a woman become pregnant or suspect she is pregnant while 
she or her partner is participating in this study, she should inform her treating physician 
immediately.  
Females of childbearing potential must h ave a negative  serum  pregnancy test at 
screening.  Females must also have a negative serum pregnancy test at baseline and 
prior to performance of any radiologic procedure or administration of study medication 
and during each visit.   Lactating mothers will discontinue breastfeeding prior to study 
enrollment.  
2.1.2.23  Pregnant or lactating females. Women of non -childbearing potential is defined as 
women who are postmenopausal (no menses for > one year) or who have had a 
hysterectomy and will not require B -hCG testing.    
2.1.3 Recruitment Strategies  
Participants representing all ethnic groups and racial categories  will be recruited for this study. 
Recruitment strategies may include a) referrals from NIH research physicians , b) referrals from  
non-NIH physicians, c) referrals f rom University of California, San Francisco (UCSF) and local 
area providers, d)  NIH Patient Recruitment website, e) NIH Clinical Center Facebook page, f) 
print media including newspapers , specialized journals and magazines, g) advertisements posted 
on inte rnet websites including  Clinicaltrials.gov  and ResearchMatch.org , local and regional 
dermatology association websites,  h) interactions with patient and physician organizations in the 
local and national dermatology community  including the National Psoriasis  Foundation , i) 
16 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 dissemination of IRB approved flyers at designated locations, j) dissemination of IRB -approved 
recruitment letters sent to potentially eligible participants identified by investigators via review 
of our patient database and charts.   
2.2 SCREENI NG EVALUATION  
➢ Assessments to be completed prior to enrollment  
• Skin biopsy for hematoxylin and eosin staining  to confirm diagnosis if prior 
confirmational biopsy has not been performed  
• Microbiologic culture of pustule confirming noninfectious etiology  
➢ Asse ssments to be completed within 8 weeks prior to enrollment  
• Quantiferon TB gold  
▪ Chest X -ray to ensure absence of radiographic evidence of tuberculosis  only if 
Quantiferon TB gold or tuberculin skin test is positive  
• Medical history and medication review  
• CBC with differential  
• Serum B -hCG in females of childbearing potential . Not required for females who are 
status -post hysterectomy  or postmenopausal (no menses for >one year) .  
• Blood urea nitrogen and serum creatinine  
• Anti-HIV-1/2 screen  
• Viral Markers Hepatitis  Screen (HBsAg and anti -HCV)  
2.3 REGISTRATION PROCEDURES  
2.3.1 Registration at the Clinical Center  
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent.  A registration Eligibility Checkli st from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Central Registration Office ncicentralregistration -l@mail.nih.gov .  
After confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to 
advise them of the acceptance of the patient on the protocol prior to the release of any 
investigational agents.  Verification of Registration will be forwarded electronically via e -mail to 
the research team. A recorder is available during non -working hours.  
2.3.2 For Participating Site Registration  
A protocol registration form will be supplied by the NIAMS study coordinator and updates will 
be provided as needed. Subject eligibility and demographic information is required for 
registration.  Once eligibil ity is confirmed , complete the protocol registration  form which 
contains the elig ibility checklist, indicating that the patient is being registered for treatment and 
send to NIAMS study coordinator. In addition, source documents supporting the eligibility 
criteria must be sent to the NIAMS study coordinator. The  NIAMS study coordinator  will notify 
you either by e -mail or fax that the protocol registration form has been received which will 
include the unique patient/subject ID number. Questions about eligibility should be directed to 
the study coordinator or PI.  Questions related to reg istration should be directed to the study 
coordinator.  
17 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 2.3.3 Treatment Assignment and Randomization/ Stratification Procedures  
Cohort  
Number  Name  Description  
1 Cohort 1  Subjects with pustular skin disease  
Arm  
Number  Name  Description  
1 Arm 1  An initial dose of  anakinra 100 mg/day will be 
administered daily via self -administered subcutaneous 
injection. If active disease  persists at this dose, anakinra 
dose may be escalated to 200 mg/day injected 
subcutaneously daily at week 4  and 300mg/day at week 
8 
 
Stratifica tions  
None  
Randomization and Arm Assignment  
This is an open -label non -randomized study. All subjects  in cohort 1 will be directly assigned to 
arm 1 . 
2.4 BASELINE EVALUATION  
HISTORY AND PHYSICAL EXAMINATION  
• Medication review  
• Directed physical examination , inclu ding body mass index calculation  
• Detailed skin examination including : 
o Total body surface area involvement (TBSAI)  
o Physician global assessment (PGA)  
o Pustular psoriasis assessme nt severity index (PPASI)  
o Palmoplantar psoriasis assessment severity index (PPPAS I), if appropriate  
BLOOD AND TISSUE  
• Complete blood count with differential  
• Serum creatinine  and urea nitrogen  
• Serum calcium, phosphorus  
• Parathyroid hormone  
• Serum 25 -OH Vitamin D  
• Hepatic panel including alkaline phosphatase  
• Serum albumin and total protein  
• Lipid Panel (total cholesterol, trig lycerides, LDL, HDL ) 
• Serum insulin level  
18 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 • Serum C -peptide  
• Acute phase reactants: erythrocyte sedimentation r ate, serum high-sensitivity C-reactive 
protein  
• Serum ferritin  
• Serologies: anti -nuclear antibody, anti -dsDNA anti bodies, anti -ENA antibodies, 
rheumatoid factor, C3, C4, CH50.  
• Quantitative serum immunoglobulins  
• HLA class I and II typing  
• Serum protein electrophoresis  
• Anti-streptolysin O titer  
• Viral Markers Hepatitis Screen ( HbsAg, Anti -HCV ) 
• Skin biops ies: up to 3 ( lesional x2, and non -lesional skin x1) (performed at the 
investigator’s discretion ) 
• Serum, plasma  and tissue  cytokine levels  
• Serum beta human chorionic gonadotropin (not required if females are status post 
hysterectomy  or postmenopausal ) 
• Serum glucose  
• Serum storage for research  
URINE  
• Urine protein electrophoresis  
• Urinalysis  
• Urine calcium, phosphorus  
QUESTIONNAIRES/MEASUREMENTS  
• Quality of life assessments/questionnaires including DLQI, SF -36, Pruritus VAS, Pain 
VAS, and Overall Disease Severity VAS (details in  Section 3.4) 
• Total body photography  (performed at the investigator’s discretion ) 
CONSULTATIONS  
The following consultations will be conducted at the investigator’s discretion:  
• Rheumatologic consultation includin g baseline joint examination with assessment by 
ACR criteria , including Health Assessment Questionnaire   
• Cardiometabolic evaluation including baseline electrocardiogram   
• Ophthalmologic examination   
• Gastrointestinal consultation  when indicated   
RADIOLOGICAL  
The following procedures will be conducted at the investigator’s discretion:  
• Total body research FDG -PET CT scan   
• Joint MRI of affected joints   
19 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3 STUDY IMPLEMENTATION  
3.1 STUDY DESIGN  
This will be a phase 2, open label, prospective interventional 1 6-week dose t itration  study.   
Patients will complete a daily diary  during the entire 16 -week study course.  Patients will be 
instructed to score the severity of rash, pustule s, itch, skin pain , joint pain and overall well -being  
into their daily diaries .  They will also  document  fever  and doses of medications  in their diaries . 
(APPENDIX B: PATIENT )   
At the baseline visit, clinical assessments, and laboratory, histopathologic and subjective data 
will be collected.   All enrolled patients will initially receive treatment with anakinra 100 mg/day 
via self -administered subcutaneous injection .  The first dose of anakinra will be administered 
under supervision in the clinic .   
At week 4 , disease response will be assessed by clinical ex am, laboratory markers and evaluation 
of patient diaries that are returned to clinic .  Determination for dose escalation will be made 
based on week 4 assessments . Those patients who do not achieve complete disease clearance 
with initial anakinra dosing  will be increased to the next incremental dose level ( see Section 
3.1.2 ).  
At week 8, patients  will return for clinical evaluation and patients who do not achieve complete 
disease clearance on anakinra have the opt ion of dose escalation up to the next incremental dose 
level . All patients will stop anakinra at week 12.  
Patients will return for an Off Study visit at week 16 , approximately 28 days after their final dose 
is administered.  Considering personal/work/travel /other obligations, a period of no more than 1 
week before or after the Week 4 , 8, or 12 visits, and 2 weeks before or after the Week 1 6 visit 
may be permitted.  
Total body photographs will be taken at baseline, week 4, week 8, week 12  and week 16  (at the 
investigator’s discretion ). 
With the patient’s consent , and at the discretion of the investigator, a skin biops y for research  
will be taken at baseline and week 12. Skin biopsies will be taken from lesional and non -lesional 
skin.  Non-lesional skin will be o btained for the purpose of comparison with lesional skin in 
immunohistochemistry, cytokine and gene expression  studies , as well as in vitro keratinocytes 
studies . 
Between scheduled clinic visits, d isease status will be assessed by telephone at weeks 1 -3, 5-7 
and 9 -11. Following discontinuation of anakinra at week 12, disease activity and adverse event 
monitoring will be assessed by telephone at weeks 13 -15. A period of no more than 3 days 
before or after weeks 1 -3, 5-7, 9-11, and 13 -15 may be permitted. The completed  patient diar ies 
will be assessed upon their return to the clinic . 
Once clinical disease is deemed to be quiescent , other immunosuppressants administered for the 
purpose of treatment of pustular skin disease may be tapered per physician discretio n.  Doses of 
anakinra and immunosuppressants will be recorded throughout the study period until week 12  in 
order to assess mean required dose of anakinra for maximum improvement of disease, and the 
number of participants who are able to taper other immunos uppressants while on anakinra 
therapy.   
20 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 The primary outcome measure  and all  secondary outcome measures  (see section  1.1.2 ), will be 
assessed by the multidisciplinary study  team at the conclusion of week 12 .  
Clinical assessment, and laboratory and subjective data will be collected monthly with the aid of 
primary care physicians during months when participants do not travel to the National Institutes 
of Health  or participating site clinic .  At any time during the  study time period,  serious  adverse  
events grade 3 or greater that are possibly, probably or definitely related to the study drug will be 
reported to the IRB .  Participants will hold therapy  immediately  and be evaluated emergently .  
Participants removed fr om study for unacceptable adverse events will be followed until 
resolution or stabilization of the adverse event.  
A total of 25 participants will be recruited for this study .  It is anticipated that 1 -2 patients per 
month will enroll onto this trial.   In order to allow for a small number of unevaluable patients, 
the a ccrual ceiling will be set at 30  patients.   Accrua l of 30 patients would be estimated to last up  
to 24 mo nths.  If 0 of the first 9 patients fail to respond to anakinra therapy  by week 12 , we w ill 
halt further patient recruitment.  
3.1.1 Dose Limiting Toxicity  
All patients will be evaluable for toxicity from the time of their first treatment with anakinra until 
the end of study partic ipation, regardless of inclusion in primary response evaluation.  
This study will utilize version 4.0 of the NCI Common Terminology Criteria for Adverse Events 
(CTCAE)  (http://ctep.cancer.gov/reporting/ctc.html ) for toxicity and adverse event reporting . 
Only those ad verse events deemed possibly, probably, or definitely related to anakinra will be 
used in the definition of dose -limiting toxicity. Greater or equal to CTCAE grade 3 toxicity in 
any enrolled subject thought to be possibly, probably or definitely associated  with anakinra  will 
be reported to the IRB .  The adverse event will be presented to the IRB and safety monitor for 
review and consideration of protocol modification including possible trial termination.  Events 
that are considered disease -related will not be considered dose limiting  or medication -induced 
adverse events . 
3.1.2 Dose Escalation  
An initial dose of anakinra 1 00 mg/day will be administered daily via self-administered 
subcutaneous injection. If pustule formation  persists at this dose , anakinra dose may be escalated  
up to 200 m g/day injected subcutaneously daily  at week 4 . Participants will be re -assessed at 
week 8 , and if pustule formation  persist s and the patient weighs ≥75kg , the dose may be 
escalated  up to a maximum 3 00 mg/day.  
 
 
 
 
 
 
 Dose Escalation  Schedu le 
Dose Level  Dose of  anakinra  
Level -1* 50mg SC daily  
Level 1  100 mg SC daily  
Level 2  200 mg SC daily  
Level 3  300 mg SC daily  (patients ≥75kg  only) 
21 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 *Patients who experience an adverse event on dose level 1 that requires dose reduction may be 
reduced to dose level -1, 50mg SC daily  (see Section  3.3).  Patients who require dose reduction 
due to an adverse event at any point in this study will not be eligible for dose escalation.  
 
Dose escalation  will follow the rules outlined in the Table below.  
 
If a patient experiences a  Grade 2  adverse event probably or definitely related to anakinra within 
7 days prior to a scheduled dose escalation, dose escalation will be postponed until res olution of 
the adverse event or a maximum of 14 days, whichever is shorter .  
3.2 DRUG ADMINISTRATION  
Anakinra is supplied in single -use 1 ml prefilled glass syringes with 27 gauge needles as a 
sterile, clear, colorless -to-white, preservative -free solution for daily subcutaneous (SC) 
administration.  Each 1 ml prefilled glass syringe contains: 0.67 ml (100 mg) of anakinra in a 
solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium 
EDTA (0.12 mg), and polysorbate 80 (0.70 mg) i n water for injection, USP.  
Patients will be instructed verbally and in writing that anakinra should be protected from light, 
stored in the refrigerator at 2oC to 8oC (36oF to 46oF) away from children, and never frozen.  
Patients will be instructed not to use any syringe if the solution appears discolored or cloudy or 
has been  at room temperature  ≥ 24 hours.   Patients will be instructed to avoid shaking the pre -
filled syringes, to use each syringe only once , and to inject the entire volume of solution.  
Patients will receive a diagram (APPENDIX C: PATIEN T HANDOUT ) of body sites where 
anakinra is to be injected , emphasizing the importance of avoiding veins, arteries and injecting 
into a new site each day.  Self-injection demonstration and technique will be provided once the 
baseline visit has concluded.  
All p atients will be given a puncture -resistant container for proper disposal of syringes after use.  Time of Assessment  Escalation  Decision Rule  
Baseline  • Enter each patient onto study at dose level 1  
Week  4 • If patient has achieved  complete clearance of 
pustul ar and plaque disease,  remain at dose level 1  
• If patient has not achieved complete pustule and 
plaque clearance, increase to next incremental dose 
level  
Week 8  • If patient has achieved  complete clearance of 
pustular and plaque disease,  remain at current dose 
level  
• If patient has not achieved complete clearance of 
pustular and plaque disease  AND patient weighs 
≥75kg , increase to next incremental dose level  
22 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 All patients will initiate anakinra therapy with one 1ml (100 mg) prefilled syringe injected 
subcutaneously daily.   Those who achieve disease quiescence on this  dose by week 4 will 
continue at this dose until week 12.  
Those who do not demonstrate disease quiescence at week 4 will increase their dose to 2 -1ml 
prefilled syringes (total of 200 mg) to be injected subcutaneously daily. Those individuals who 
weight >7 5kg and do not demonstrate disease quiescence by week 8 on anakinra 200 mg/day 
will be instructed to increase their dose to 3 -1ml prefilled syringes (total of 300mg) injected 
subcutaneously daily.  
Patients who miss a dose will be instructed to  administer t he dose as soon as they remember.  
However, if it is almost time to administer the next dose, the patient will be directed to skip the 
missed dose and proceed with their regularly scheduled dose.  Patients will be reminded to avoid 
double -dosing in an effo rt to make up the missed dose.  
If a patient misses a dose of study drug, it will be recorded in the med ical record and on the CRF. 
Missed dose s will not be reported to the IRB as a protocol deviation unless the patient misses >5 
doses per month.  
3.3 DOSE MODIF ICATIONS  
All dose modifications must be discussed with the PI. T his study will utilize version 4 .0 of the 
NCI Common Terminology Criteria for Adverse Events (CTCAE) 
(http://ctep.cancer.gov/reporting /ctc.html ) for toxicity and adverse event reporting.  Expected 
pre-existing or concurrent manifestations of inflammatory pustular dermato ses include fatigue, 
malaise, pain, pruritus , arthritis, enthesitis, alopecia, pustular and papular skin lesions, 
hypo pigmentation, hyperpigmentation, skin dryness, nail changes, koebnerization at sites of 
trauma or injections, uveitis, conjunctivitis, rash, hypocalcemia, hypoalbuminemia and 
leukocytosis .  Any of the above symptoms newly presenting after initiation of ana kinra must be 
carefully evaluated for attribution, i.e. , new skin rash may be biopsied to determine drug reaction 
versus pustular dermatosis.   See APPENDIX  D: DOSE MODIFICATION FLOW CHART  
for Dose Modification F low Chart. 
 
Adverse event  CTCAE grade/attribution  Protocol Action  
Any adverse event  (excluding 
infection, treatment -related 
malignancy)  Grade 2 >7 days that is probably 
or definitely related to anakinra.  Hold study drug; *If AE 
resolves to ≤ grade 1 or 
baseline within 14 days:  
resume dose at same dose 
level . ** If AE does not 
resolve to ≤ grade 1 or 
baseline within 14 days: 
patient comes off drug.   
Any adverse event  (excluding 
infection, treatment -related 
malignancy)  Same grade 2 >7 days recurs 
that is prob ably or definitely 
related to anakinra.   
 Hold study drug; *If AE 
resolves to ≤ grade 1 or 
baseline within 14 days: 
decrease dose by 1 dose 
level. **If AE does NOT 
23 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 resolve to ≤ g rade 1 or 
baseline within 14 days: 
patient comes off drug. 
Any adverse even t (excluding 
infection, treatment -related 
malignancy)  Same grade 2 >7 days 
recurs after dose reduction 
that is probably or definitely 
related to anakinra.   
 Patient comes off drug.  
Any adverse event  (excluding 
infection, treatment -related 
malignancy)  Grade 3 that is probably or 
definitely related to 
anakinra.   
 Hold study drug; *If AE 
resolves to ≤ grade 1 or 
baseline within 14 days: 
decrease dose by 1 dose 
level. **If AE does NOT 
resolve to ≤ grade 1 or 
baseline within 14 days: 
patient comes off drug. 
Any adverse event  (excluding 
infection, treatment -related 
malignancy)  Same grade 3 recurs after dose 
reduction that is probably or 
definitely related to anakinra.  Patient comes off drug. 
Any adverse event  (excluding 
infection, treatment -related 
malignancy)  Grade 4 that is probably or 
definitely related to 
anakinra.   
 Patient comes off drug. 
Infec tion Grade 2 that is probably or 
definitely related to anakinra  Hold study drug until 
completion of antibiotic 
course  and resolution of 
infection , then restart at same 
dose level . 
Infection  Grade 2 recurs that is probably 
or definitely related to anakinra  Hold study drug until 
completion of antibiotic 
course  and resolution of 
infection , then decrease dose 
by 1 dose level.  
Infection  Grade 2 recurs after dose 
reduction that is probably or 
definitely related to anakinra  Patient comes off drug. 
Infection  Grade 3 that is probably or 
definitely related to anakinra  Patient comes off drug. 
Infection  Grade 4 Patient comes off drug. 
Treatment -related 
malignancy  Grade 3  Patient comes off drug. 
Treatment -related Grade 4  Patient comes off drug. 
24 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 malignancy  
 
Exce ptions to the above treatment modifications:  
1. Alopecia any grade  
2. Grade 2 anorexia  
3. Grade 2 fever  
4. Grade 2 fatigu e 
5. Grade 2 flu -like symptoms  
6. Grade 2 chills  
7. Grade 2 headache  
8. Grade 2 hypoalbuminemia  
9. Hypocalcemia toxicity grade should be assigned based on the c alcium level corrected for  
degree of hypoalbuminemia according to the following formula: albumin 1 gram/dL: total 
calcium 0.2 mmol/L. Ionized calcium can also be used to assess toxicity.  
10. Grade 2 injection site react ion 
11. Grade 2 malaise  
12. Grade 2 nausea  
13. Grad e 2 dry skin  
14. Grade 2 skin or soft tissue infection  
15. Grade 2 paronychia  
16. Basal cell carcinoma or squamous cell carcinoma of the skin  
 
Doses withheld while recovering from an adverse event should not be made up.  
3.4 QUALITY OF LIFE TOOLS /QUESTIONNAIRES  
The follow ing quality of life  instruments will be administered  at baseline, week 4, week 8 and 
week 12 : 
1. 36-item Short Form Health Survey i s a self -administered multi -purpose, short -form 
health survey with 36 questions yielding an 8 -scale profile of functional health  and well -
being scores as well as psychometrically -based physical and mental health summary 
measures and a preference -based health utility index.   It is a generic measure.  This scale 
has been used for the measurement of general health status quality of li fe.  This 
questionnaire will be administered at baseline, week 4, week 8 , week 12  and week 16 .  
(10-12 minute s) (APPENDIX E: SHORT FORM  36 (ENGLISH AND SPANISH )) 
2. Dermatology Life Quality Instrument (DLQI) is a 10 -item questionnaire which assesses 
impact of skin disease on life quality.  It is a validated questionnaire which has been used 
in 33 different skin conditions in 32 countries and is available in 55 languages.  It is the 
most frequently used instrument in s tudies of randomized controlled trials in 
dermatology.   This questionnaire will be administered at baseline, week 4, week 8 , week 
12 and week 16 .  (2 minutes ) (APPENDIX F: DERMATOLOGY LIFE QUALITY 
(ENGLISH AND SPANISH )) 
25 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3. Pruritus Visual Analog Scale  is a self -administered psychometric response instrument 
which measures subjective characteristics or attitudes that cannot be directly measured.  
It ranges from 0 -10.  This scale has been used for measurement in a variety  of 
dermatologic settings . This questionnaire will be administered at baseline, week 4, week 
8, week 12  and week 16 .  (1 minute ) (APPENDIX H: PUSTULAR DERMATOSIS 
CLINICAL ASSESSMENT SCALE ) 
4. Skin Pain Visual Analog S cale is a self -administered psychometric response instrument 
which measures subjective characteristics or attitudes that cannot be directly measured.  
It ranges from 0 -10.  This scale has been used for measurement in a variety of 
dermatologic settings .  This questionnaire will be administered at baseline, week 4, week 
8, week 12  and week 16 . (1 minute ) (APPENDIX H: PUSTULAR DERMATOSIS 
CLINICAL ASSESSMENT SCALE )  
5. Joint  Pain Visual Analog Scale is a self -administered psychometric response instrument 
which measures subjective characteristics or attitudes that cannot be directly measured.  
It ranges from 0 -10.  This scale has been us ed for measurement in a var iety of 
dermatologic settings.  This questionnaire will be adm inistered at baseline, week 4, week 
8, week 12  and week 16 .  (1 minute ) (APPENDIX H: PUSTULAR DERMATOSIS 
CLINICAL ASSESSMENT SCALE ) 
6. Overall Disease Severity Visual Analog Scale is a self -administered psychometric 
response instrument which measures subjective characteristics or attitudes that cannot be 
directly measured.  It ranges from 0 -10.  This scale has been used for measurement in a 
variety of health settings .  This questionnaire will be administered at baselin e, week 4, 
week 8 , week 12  and week 16 .  (1 minute ) (APPENDIX H: PUSTULAR 
DERMATOSIS CLINICAL ASSESSMENT SCALE )  
7. Health Assessment Questionnaire (HAQ) is a self -administered questionnaire which aims 
to assess healt h-related quality of life longitudinally based on five patient -centered 
dimensions: disability, pain, medication effects, costs of care, and mortality. This 
instrument is used in the calculation of the ACR70. This questionnaire will be 
administered with ea ch rheumatology evaluation. (5 minutes) (APPENDIX I: HEALTH 
ASSESSMENT QUESTIONNAIRE ) 
 
Completed questionnaires will be maintained in the subject’s research chart until study analysis 
is completed.  
 
26 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3.5 STUDY FLOWCHA RT 
 
 
 
 Baseline: clinic visit  
 History and physical exam  
 Safety laboratory studies (blood and uri ne) 
 Research L aboratory studies (blood)  
 Serum B -hCG (required for females of childbearing potential)  
 Skin examination (TBSAI, PGA , PPASI, PPPASI ) 
 Skin biopsy of lesional and non -lesional skin for IHC, gene expression and cytokine studies*  
 Joint assessment (ACR criteria , including Health Assessment Questionnaire )  
 Ophthalmologic examination  * 
 Gastrointestinal evaluation (if history of gastrointestinal symptoms)  * 
 Cardiometabolic  evaluation * 
 FDG PET/ CT scan * 
 QOL/questionnaires  
 Total body photographs  * 
 Teachi ng 
 Dispense study drug  
Weeks 1, 2, 3  (+/- 3 days)  (no clinic visit)  
 Telephone assessment  
 AE monitoring  
 
Weeks 5, 6, 7 (+/- 3 days)  (no clinic visit)  
 Telephone assessment  
 AE monitoring  
 Week 4  (+/- 1 week) : clinic visit  
 Updated history & s kin examination (TBSAI, PGA , PPASI, PPPASI ) 
 Joint assessment by ACR criteria * (l if no evidence o f joint disease, 
including Health Assessment Questionnaire)  
 Follow up serum and urine laboratory studies  
 Serum B -hCG (required for females of childbearing potential)  
 QOL/Questionnaires  
 Total body photographs *  
 Dose titration to 200 mg/day as appropriate f or partial  and non - 
responders  
 Teaching/reinforcement  
 Dispense study drug  
 
Week 8  (+/- 1 week) : clinic visit  
 Updated history & s kin examination (TBSAI, PGA , PPASI, PPPASI ) 
 Joint assessment by ACR criteria * (if no evidence of joint disease, 
including Healt h Assessment Questionnaire)  
 Follow up serum and urine laboratory studies  
 Serum B -hCG (required for females of childbearing potential)  
 QOL/Questionnaires  
 Total body photographs   
 Dose titration to 300 mg/day for partial and non -responders weighing 
>75kg  
 Teaching/reinforcement  
 Dispense study drug  
 
27 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
*Denotes procedure/consultation that is to be performed at the discretion of the investigator.  
 
 
 Weeks 9, 10, 11 (+/- 3 days)  (no clinic visit)  
 Telephone assessment  
 AE monitoring  
 
Week 12  (+/- 1 week) : clinic visit  
 Updated histo ry & post -treatment skin examination (TBSAI, PGA , PPASI, PPPASI ) 
 Follow up serum and urine  safety  laboratory studies  
 Follow up serum research  laboratory studies  
 Serum B -hCG (required for females of childbearing potential)  
 Post-treatment skin biopsy  of lesi onal and nonlesional skin for IHC and gene expression studies*  
 Post-treatment joint assessment by ACR criteria  (including Health Assessment Questionnaire)  
 Post-treatment ophthalmologic examination * 
 Post-treatment gastrointestinal evaluation (if history of gastrointestinal symptoms) * 
 Post-treatment cardiac evaluation  including electrocardiogram * 
 Post-treatment total body FDG PET CT scan * 
 Post-treatment QOL/ questionnaires  
 Post-treatment serum and urine laboratory studies  
 Total body photographs * 
 
Week 16  (+/- 2 weeks)  (clinic visit ): 
 Post-treatment skin examination (TBSAI, PGA , PPASI, PPPASI ) 
 Post-treatment joint assessment by ACR criteria * (if no evidence 
of disease, includin g Health Assessment Questionnaire)  
 End-of-study labs and urines   
 Total body photographs*  
 QOL/questionnaires  
 Collection of patient diaries  
 AE monitoring  
 Weeks 13, 1 4 15 (+/ - 3 days)  (no clinic visit)  
 Telephone assessment  
 AE monitoring  
 
Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
 3.6 STUDY CALENDAR   
 Screening 
≤8 weeks  
prior to 
enrollment  Baseline - 
up to 
drug 
initiation
a Weeks  
1, 2, 3 
(+/- 3 
days)    Week 
4 (+/- 
1 
week)  Weeks 
5, 6, 7  
(+/- 3 
days)    Week 
8 (+/- 
1 
week)  Weeks 
9, 10, 
11  
(+/- 3 
days)    Week 
12 (+/- 1 
week) :  
End of 
Treatm
ent Weeks 
13, 14, 
15  
(+/- 3 
days)  Week 16   
(+/- 2 
weeks) :  
Post 
Therapy 
Follow -
upa 
Eligibility  X X-update   Clinic 
visit  Clinic 
visit  Clinic 
visit   
Consent   X         
H&P  X X- 
update   X  X  X  X 
NIH Advanced Directives 
Formb  X         
Medication review  X X- 
update   X  X  X  X 
Dose titrationc    X  X     
Telephone surveillance    X  X  X  X  
Immu nosuppressant drug 
taper (per MD discretion)      X X X X   
CBC/diff, serum creatinine 
and urea nitrogen, hepatic 
panel with alk. phos, serum B -
hCG   X X  X  X  X  X 
29 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  Screening 
≤8 weeks  
prior to 
enrollment  Baseline - 
up to 
drug 
initiation
a Weeks  
1, 2, 3 
(+/- 3 
days)    Week 
4 (+/- 
1 
week)  Weeks 
5, 6, 7  
(+/- 3 
days)    Week 
8 (+/- 
1 
week)  Weeks 
9, 10, 
11  
(+/- 3 
days)    Week 
12 (+/- 1 
week) :  
End of 
Treatm
ent Weeks 
13, 14, 
15  
(+/- 3 
days)  Week 16   
(+/- 2 
weeks) :  
Post 
Therapy 
Follow -
upa 
Blood sampling: calcium, 
phosphorus, albumin, total 
protein, ESR, hs-CRP, serum 
c-peptide   X  X  X  X  X 
Urine sampling: UA, calcium, 
phosphorus   X  X  X  X  X 
Ferritin , lipid panel, serum 
insulin, serum glucose   X         
Serum and urine protein 
electrophoresis, Parathyroid 
hormone, Serum 25 -OH 
Vitamin D, anti -nuclear 
antibody, anti -dsDNA 
antibodies, anti -ENA 
antibodies, rheumatoid factor, 
C3, C4, CH50, HLA typing, 
quantitative serum 
immunoglobulins, anti -
streptolysin O titer   X         
HIV screen and hepatitis 
screen  X          
Total body photographs    X  X  X  X  X 
30 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  Screening 
≤8 weeks  
prior to 
enrollment  Baseline - 
up to 
drug 
initiation
a Weeks  
1, 2, 3 
(+/- 3 
days)    Week 
4 (+/- 
1 
week)  Weeks 
5, 6, 7  
(+/- 3 
days)    Week 
8 (+/- 
1 
week)  Weeks 
9, 10, 
11  
(+/- 3 
days)    Week 
12 (+/- 1 
week) :  
End of 
Treatm
ent Weeks 
13, 14, 
15  
(+/- 3 
days)  Week 16   
(+/- 2 
weeks) :  
Post 
Therapy 
Follow -
upa 
Total body surface a rea 
involvement measurement   X  X  X  X  X 
PGA scoring   X  X  X  X  X 
Skin biops y  Xg Xh      Xh   
Quantiferon T gold  Xd          
Chest X -ray if positive 
Quantiferon TB Gold  Xd          
Microbiologic culture of 
pustule confirming 
noninfectious etiolog y X          
FDG -PET CT scan    X      X   
Joint MRI    X      X   
Research blood sampling   X      X   
Rheumatology Consultation  
including ACR assessmente  X  X  X  X  X 
Cardiometabolic evaluation  
including electrocardiogram    X      X   
Ophthalmologic  examination    X      X   
Gastrointestinal consultation    X      X   
31 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  Screening 
≤8 weeks  
prior to 
enrollment  Baseline - 
up to 
drug 
initiation
a Weeks  
1, 2, 3 
(+/- 3 
days)    Week 
4 (+/- 
1 
week)  Weeks 
5, 6, 7  
(+/- 3 
days)    Week 
8 (+/- 
1 
week)  Weeks 
9, 10, 
11  
(+/- 3 
days)    Week 
12 (+/- 1 
week) :  
End of 
Treatm
ent Weeks 
13, 14, 
15  
(+/- 3 
days)  Week 16   
(+/- 2 
weeks) :  
Post 
Therapy 
Follow -
upa 
QOL/questionnairesf  X  X  X  X  X 
Daily scoring diary   Start Day 
0  X--------------------------------------------------------------------------- X 
AE Monitoring   START  X X X X X X X X 
 
a Additional clinical labs may be obtained as indicated at baseline and follow up visits  
b As indicated in section 10.3, all subjects  at NIH  will be offered the opportunity to complete an NIH advanced direct ives form.  This should be done preferably 
at baseline but can be done at any time during the study as long as the capacity to do so is retained.  The completion of the  form is strongly recommended, but 
is not required.  
c If escalation cri teria are met (s ee Section 3.2) 
d Within 8 weeks of enrollment  
e If the rheumatology consult is done at Week 0 , the patien t will be seen again at Week 12 . If there is evidence of joint disease, patients will be strongly 
encou raged to have rheumatology consult during all clinic visits (Weeks 0, 4,8, 12 and  16) 
f QOL/questionnaires (see Section 3.4) 
g Skin biopsy for hematoxylin and eosin staining to confirm diagnosis if prior confi rmational biopsy has not been performed  
h Performed at the investigator’s discretion for research purposes  
Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
 3.7 SURGICAL GUIDELINES  
Skin biopsies of lesional and nonlesional skin  will be taken at baseline  and week 12 . Skin biopsy 
procedure will be explained  to the patient and informed consent will be obtained. The risks of 
infection, scarring, nerve damage, pigment change, numbness, recurrence, bleeding, pain, and 
allergy to anesthesia will be reviewed. Sterile preparation of the proposed bio psy site will be  
performed . The biopsy site will be locally anesthetized . Size of punch biopsies will be u p to 
6mm. One punch biopsy will be performed from nonlesional skin, and up  to two punch biops ies 
will be  performed  from lesional skin. We will place sutures for h emos tasis. Petrolatum and 
bandage will be applied  to the wound site and w ound  care will be  reviewed . Written wound care  
instructions w ill be  given. We will instruct the patient regarding  suture removal.  
3.8 OPHTHALMOLOGIC PROCEDURES  
3.8.1 Ophthalmic Examination with Dil ation  
Dilation of the pupils will cause temporary glare and blurring of vision. Rarely an allergic 
reaction or infection secondary to contaminated drops can occur. Dilating drops can also cause a 
sudden increase of pressure (acute glaucoma) in eyes that ar e already predisposed to develop this 
condition. There is little risk of glaucoma being triggered in this way, but if it is, treatment will 
be available.  
 
3.8.2 Fluorescein Angiography  (if clinically indicated)  
The participant’s skin may turn yellow for several hours. The yellow color will disappear as the 
kidney filters the dye from the body. Because the dye passes through the kidneys, the urine will 
turn dark orange for up to 24 hours after the exam. Some participants may be slightly nauseous 
(upset stomach) du ring the exam, but their nausea usually lasts only a few seconds. If the dye 
leaks out of the vein during the injection, some of the skin around the injection site may feel 
mildly uncomfortable or become yellow. The mild discomfort usually lasts only a few  minutes, 
and the yellow color goes away in a few days.  
 
Sometimes participants have an allergic reaction to the dye, but this rarely happens. Oral 
antihistamines are usually used to treat this or the antihistamines may be injected if the 
symptoms are sev ere. Very rarely, a participant may have a severe allergic reaction that causes 
respiratory distress and shock (“anaphylaxis”), which can be life -threatening. Trained personnel 
with drugs or, possibly, surgery would treat this immediately.  
 
3.8.3 Optical Coheren ce Tomography (OCT)  
There is no medical risk from OCT.  
 
3.8.4 Microperimetry  
There is no medical risk from microperimetry . 
33 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3.9 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to documenting removal from  study , effort must be made to have all  subjects complete a 
safety visit approximately 28 days following the last dose of study therapy.  
3.9.1 Criteria for removal from protocol therapy  
• Completion of 12-week anakinra therapy   
• Noncompliance with protocol procedures  
• Pregnancy  
• Participant requests to be  withdrawn from active therapy  
• Non-allergic toxicity or observed allergic reaction to anakinra  
• Investigator discretion  
• Positive pregnancy test  
• Death  
 
3.9.2 Off-Study Criteria  
• Completion of post -treatment week 16 off -study visit  
• Participant requests to be withdr awn from study  
• Death  
3.9.3 Off Protocol Therapy and Off Study Procedure  
3.9.3.1  Clinical Center Off Protocol Therapy and Off-Study Procedure  
Authorized staff must notify Central Registration Office (CRO) when a subject is taken off 
protocol therapy and when a subject is  taken off-study. A Participant Status Update Form  from 
the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted ema il to:  NCI Central Registration Office 
ncicentralregistration -l@mail.nih.gov . 
3.9.3.2  Participating Site Off Protocol Therapy and Off-Study Procedure  
The Participant Status Update Form will be supplied  by the NIAMS study coordinator. Send the 
completed form to the NIAMS study coordinator.  
3.10 BASIC AND CLINICAL SCIENCE RESEARCH PLAN 
3.10.1  Characterize and d issect inflammatory pathways in participant lesional skin  and 
peripheral blood mononuclear cells  
3.10.1.1  Immunohist ochemical studies  
Immunohistochemistry studies will be utilized to characterize  the hematopoietic inflammatory 
infiltrate in lesional skin , including neutrophils (neutrophil elastase and CD15), myeloid 
dendritic cells (blood dendritic cell antigen [BDCA] -1, CD11c, BDCA -3), macrophages 
(CD163) and T lymphocytes (CD3).   
Two-color immunofluorescence will be performed to determine CARD14+ cells (e.g., CARD14 
versus CD11c, CARD14 versus CD163)55-57.  
 
34 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3.10.1.2  Global gene express ion studies  
Lesional and nonlesional skin biopsies obtained before and after treatment with anakinra will be 
assayed for gene expression profiles  with microarray assays .  Genes associated with immune 
dysregulation and cell differentiation will be assessed and compared between patients.  Gene 
expression will be confirmed by reverse transcriptase polymerase chain reaction (RT -PCR) and 
quantitative RT -PCR for low -expressing cytokines.   
For patients with systemic inflammation characterized by fever, marked leu kocytosis and /or 
elevated acute phase reactants, we will perform gene expression studies on peripheral blood 
mononuclear cells (PBMCs) before and after treatment with anakinra .   
These profiles will be compared with gene expression profiles from lesional s kin in patients with 
known DIRA (n=2), CARD14 mutations (n=3), and familial psoriasis (n=5).  Additional analytic 
approaches will include Ingenuity Pathways Analysis (IPA), and Gene Set Enrichment Analysis 
(GSEA)55, 58, 59.   
Genomics studies will not be performed on this protocol. Genomics studies for pustular 
dermatoses will be performed on protocol 17-I-0016 .  At the time of enrollment, p atients will be 
offered simultaneous enroll ment  in protocol 17-I-0016 . (Secti on 5.2) 
3.10.1.3  Cytokine studies  
We will perform skin and  serum studies before and after anakinra therapy to assess levels of 
inflammatory cytokines including IL -1b, IL -6, IL -8, IL -17, IL -21, IL -22, IL -23, G -CSF and TNF  
using RT-PCR Luminex  assay.    
3.10.2  Evaluate systemic inflammation  in participants with pustular dermatoses using imaging 
modalities and biomarkers of cardiometabolic disease  
3.10.2.1  Fluoro -Deoxy -Glucose PET CT Imaging for Body Metabolism  
We will utilize a technique fo r quantifying the extent of atherosclerosis in the aorta by 
combining standard uptake values (SUVs) in the aortic wall obtained using FDG -PET with 
volumetric data provided by CT 60, 61.  FDG uptake will be  measured in all six segments of the 
aorta by calculating the mean combining SUVs for each segment. On each axial CT image, 
region -of-interest tracings along the inner and outer wall contours of the aorta are created. The 
average SUVs are then multiplied by the wall  volume to calculate the total amount of vascular 
inflammation for each segment of the aorta. This total amount of vascular inflammation of each 
aortic segment can be used as an indicator of the extent of the atherosclerotic process by 
combining the functi onal and structural data provided by FDG -PET and CT.  
 
Subjects will fast for six hours prior to imaging.  Blood glucose will be checked and should be in 
the 100 -160 mg/dL range to ensure an optimum study.   The patient is injected with 10 mCi of 
18-Fluoro -Deoxy glucose (FDG) and then rests for 60 minutes.  The effective radiation dose of 
two 10 mCi injections  of FDG is 2.6 rem .  The subject will be positio ned in a 16 -slice PET CT 
scanner (GE, Discovery ST).  The CT images acquired as part of the PET CT exami nation will 
be acquired using a low dose technique during quiet breathing.  The CT images will allow for 
attenuation correction of the PET emission data, and will aid in the accurate anatomical 
35 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 localization of sites of radiotracer uptake seen on PET images .  The scanning time is typically 45 
minutes. The CT and PET images are co -registered and can be viewed and interpreted.  
The presence of brown fat is inferred from the following:  
• FDG uptake in known usually symmetric distribution in the body  
• Correspondin g CT appearances consistent with fat at a site of FDG uptake  
 
Whole body metabolism can be assessed by visual inspection of scout images and then 
quantified using standardized uptake volumes (SUV).  
3.10.2.2  Evaluating biomarkers of cardiometabolic disease  
We will  evaluate biomarkers of cardiovascular disease by assaying pro -atherogenic lipoproteins 
via nuclear magnetic resonance spectroscopy (NMR), and high density lipoprotein (HDL) 
function via HDL cholesterol efflux capacity.   
3.10.3  Evaluate keratinocyte responses to t argeted inflammatory stimuli including infectious 
agents and danger molecules.  
 
3.10.3.1  Characterize response to Toll -like receptor (TLR) stimulation  
Our preliminary data shows that keratinocytes from patients with monogenic forms of pustular 
diseases not only pr oduce higher levels of proinflammatory cytokines and chemokines in 
response to stimulation, but also demonstrate hyper - and parakeratosis histologically, thus 
indicating abnormal differentiation and abnormal apoptosis. We will create keratinocyte cell 
lines to assess whether keratinocytes from patients with pustular lesions have abnormal 
responses to TLR stimulation.  We have made keratinocyte cell lines from skin biopsies from 
both healthy individuals and patients with monogenic pustular skin diseases (hea lthy controls, 
n=6; DIRA, n=2; CARD14, n=1).  We will create keratinocyte cell lines from study participants 
with genetically -undefined pustular diseases.  The keratinocyte cell lines will be immortalized as 
recently described in the presence of feeder cel ls and a ROCK -inhibitor.62  
Keratinocytes from healthy controls, patients with monogenic forms of pustular disease, and 
patients with genetically -undefined pustular diseases will be exposed to a panel of TLR 
stimulants.  We will use gene expression profiling to assess the impact of TLR stimulation on 
cell differentiation.   
 
3.10.3.2  Compare affected and una ffected keratinocytes and fibroblasts with those of patients 
with monogenic pustular diseases and genetically -undefined pustular diseases in an 
organotypic raft culture system  
We will study signaling pathway effects on keratinocyte proliferation and diffe rentiation in an 
environment that closely mimics human epidermis.  The organotypic raft culture system has been 
shown to mimic the functional alterations observed in inflammatory disease63.  Immortalized 
keratinocyt es (as described above)  will be used to generate rafts to examine the response of these 
cells to stimuli from cytokines and TLR agonists.    
36 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 We will evaluate inflammatory and differentiation properties in keratinocytes from study 
participants.  Immunohistoc hemical techniques will be applied to raft cultures to evaluate 
alterations in markers of proliferation (PCNA, Ki67) and differentiation (epidermal 
differentiation markers including loricrin, filaggrin, involucrin, keratin 1, keratin 10) between 
unaffected  controls and patient samples.   Preliminary characterization by western blot analysis of 
immortalized keratinocytes from unaffected controls differentiated in culture with calcium64  
indicate that this methodology is also applicable for these samples.   
4 CONCOMITANT MEDICATI ONS/MEASURES  
No drug -drug interaction studies with anakinra in human subjects have been conducted.  
Toxicological and toxicokinetic studies in rats did not demonstrate alterations in the clearance or 
toxicological profile of either methotrexate or anakinra when the two agents were admini stered 
together.  In two studies  of concurrent etanercept and anakinra therapy , patients  were treate d for 
up to 24 weeks  and a 7% rate of serious infections was observed, which was higher than when 
either agent was used alone.  Two percent of patients (3/139) treated concurrently with anakinra 
and etanercept developed neutropenia (ANC < 1 x 109/L).  Patients enrolled into this study will 
be required to discontinue etanercept  (Enbrel®), or other TNF -inhibitor  therapy, including  
infliximab (Remicade®), golimumab (Simponi®) and adalimumab (Humira®), certolizumab  
(Cimzia®), and other TNF -inhibi ting agents suc h as thalidomide at least three  half lives prior to 
initiation of anakinra therapy because of a potential increased risk of infection  (APPENDIX A: 
FORBIDDEN DRUGS ).  All medication  changes  will be recorded in the patient daily diary.  
4.1 SUPPORTIVE CARE 
Patients will be screened thoroughly and will be instructed by medical providers to detect and 
report early signs of side effects related to anakinra.  Patients will receive instructions on 
monitoring, recording, and re porting side effects or adverse events.  Should subjects experience 
an adverse event, they will be instructed to contact the study team immediately and to anticipate 
a clinic visit for evaluation and possible treatment.  
4.1.1 NIH Patients  
Communication and consu ltation with physicians and nurses is available 24 hours a day, 7 days a 
week through the nursing unit of the NIAMS Dermatology Clinic or the NIH page operator at 
(301) 496 -1211.  When possible, subjects requiring supportive care will be evaluated at the N IH. 
If a subject is unable to be seen at the NIH, telephone consultation will be available, as described 
above, to assist other practitioners involved in the patient’s care.   
4.1.2 UCSF  Patients  
Communication and consultation with physician and study coordinato r is available 24 hours a 
day, 7 days a week through the UCSF Dermatology Clinic, the UCSF page operator or the 
confidential patient portal service , MyChart. When possible, subjects requiring supportive care 
will be evaluated at UCSF. If a subject is unabl e to be seen at UCSF, telephone consultation will 
be available, as described above, to assist other practitioners involved in the patient’s care.  
37 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 5 BIOSPECIMEN COLLECTI ON 
5.1 CORRELATIVE STUDIES F OR RESEARCH   
The research nurse will be respon sible for coordina ting transport of biospecimen samples 
collected throughout the study . 
5.1.1 Blood (Clinical and Research Samples)  
Blood will be obtained from each patient during the initial and subsequent visits.  All blood 
volumes to be drawn will remain within the NIH Clinic al Center guidelines for adult patients.  
Only clinical laboratory and/or microbiology results will be returned to the patient or their 
designated primary care provider (PCP).  In rare instances, blood drawing limit may exceed the 
expected volume as a resu lt of loss or damage of blood samples, repeating the tests in order to 
validate unusual or erroneous results, will not exceed the limits set forth by the NIH CC MEC 
policy .  The amount of blood drawn from adults for research purposes shall not exceed 10.5 
mL/kg or 550 mL, whichever is smaller, over any eight week period.  Additionally, aliquots of 
blood may be coded and shared with other collaborating researchers/investigators, under the 
auspices of appropriate material transfer agreements.  
5.1.1.1  Clinical bloods  
Blood samples will be analyzed for standard medical evaluations  as outlined in Section  2.   
5.1.1.2  Research bloods  
Research blood will be drawn to examine serologic and immunological markers, including but 
not limited  to cytokines, cardiometabolic markers including fasting insulin and glucose  and gene 
expression studies  (see section 3.10.1.2 ).  
5.1.1.3  Research biopsies  
At the investigator’s discretion, research skin punch biopsies will be collected from lesional and 
nonlesional skin at baseline and week 12 to  perform immunohistochemistry studies, cytokine 
studies and gene expression studies.  Keratino cyte responses to infectious and inflammatory 
stimuli will be assessed.  Keratinocy tes will also be used to make cell lines which will then be 
used to study keratinocytes inflammatory and differentiation properties in vitro.  
5.1.2 Research samples collected at UCSF  
All b lood (Sodium Heparin, SST, EDTA, Pax Gene tubes) and biopsy specimens in D MEM 
culture medium and biopsy specimens in RNAlater will be shipped to NIH in an ambient thermal 
container overnight to be received within 24 hours of collection.  Specimens should be shipped to 
the below address:  
Yan Huang  
10 Center Dr., Room 11C-216 
Bethe sda, MD 20892  
301-761-7637  
yan.huang2@nih.gov  
5.2 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Please refer to protocol  17-I-0016  for details.  
38 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 Whole blood, blood products, tissue,  and RNA from all subjects will be  stored indefinitely in the 
laboratories of Dr. Goldbach -Mansky  and Dr. Nehal Mehta,  and coded by study date and 
number.  Patient  samples will be identifiable using a database that is only accessible to the 
researchers intimately involved with the protocol.  The s amples themselves  will not have direct 
patient i dentifiers.   
Effective with amendment J, a ll patients  will be offered simultaneous enroll ment  in protocol  17-
I-0016 , which aims to comprehensively evaluate patients with inflammatory multi -system 
diseases cl inically, genetically, immunologically, and endocrinologically , and evaluate  long term 
outcome s and biomarkers.   If the patient consents to both studies, data collected on protocol 17-
I-0016  will be correlated with data collected on our protocol.    
NOTE: Prior to amendment J, subjects were offered simultaneous enrollment onto protocol 03 -
AR-0173, for the purposes described above. However, d ata from protocol 03 -AR-0173 has been 
transferred to protocol 17 -I-0016.  
If the patient withdraws consent , the particip ant’s data will be excluded from future distributions, 
but data that have already been distributed for approved research use will not be able to be 
retrieved.  
All specimens obtained in the protocol are used as defined in the protocol.  Any specimens that 
are remaining at the completion of the protocol will be stored in the conditions described below.  
The study will remain open so long as  sample or data analysis continues.  Samples from 
consenting subjects will be stored until they are no longer of scientif ic value or if a subject 
withdraws consent for their continued use, at which time they will be destroyed.  The PI will 
report any loss or destruction of samples to the NIH Intramural  IRB as soon as he is made aware 
of such loss.  
The PI will report d estroyed samples to the IR B if samples become unsalvageable because of 
environmental factors (ex. broken freezer or lack of dry ice in a shipping container) or if a patient 
withdraws consent.  Samples will also be reported as lost if they are lost in trans it between 
facilities or misplaced by a researcher.  Freezer problems, lost samples or other problems 
associated with samples will also be reported to the IRB, the NCI Clinical Director, and the 
office of the CCR, NCI.  
 
Samples at NIH will be ordered in CRIS and tracked through a Clinical Trial Data Management 
system .  Should a CRIS screen not be available, the CRIS downtime procedures will be 
followed .  Samples will not be sent outside NIH without IRB notification and an executed MTA.  
6 DATA COLLECTION AND  EVALUATION  
6.1 DATA COLLECTION  
Data will be collected by investigators during visits and recorded in the patient’s permanent 
medical record. Data will be entered into the C3D database.  Protocol -specific case report forms 
will be developed and completed by t he clinical teams.  Data collection forms may include the 
clinical and laboratory information obtained from standard clinical evaluations at study entry, 
39 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 organ -specific scales, selected research laboratory data and the follow -up outcomes that are 
necessary  for determination of primary and secondary endpoints.    
Personal identifiers will not be used when collecting and storing data.  An enrollment log will be 
maintained in the regulatory binder/file which is the only location of personal identifiers with 
unique subject identification number.  
The PI will be responsible for overseeing entry of data into an in -house password protected 
electronic system and ensuring data accuracy, consistency and timeliness. The principal 
investigator, associate investigators/res earch nurses and/or a contracted data manager will assist 
with the data management efforts. All data obtained during the conduct of the protocol will be 
kept in secure network drives or in approved alternative sites that comply with NIH security 
standards.  Primary and final analyzed data will have identifiers so that research data can be 
attributed to an individual human subject participant.  
All adverse events, including clinically significant abnormal findings on laboratory evaluations, 
regardless of sever ity, will be followed until return to baseline or stabilization of event. Patients 
will be followed for adverse events for  28 days  after removal from study treatment or until off -
study, whichever comes first.  
An abnormal laboratory value will be recorded i n the database as an AE only if the laboratory 
abnormality is characterized by any of the following:  
• Results in discontinuation from the study  
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic intervention  
• Is associ ated with death or another serious adverse event, including hospitalization.  
• Is judged by the Investigator to be of significant clinical impact  
• If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details a bout the action taken with respect to the test drug and about the patient’s 
outcome.  
End of study procedures:  Data will be stored according to HHS , FDA regulations  and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of data:  Should we become aware that a major breach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified.  
6.2 RESPONSE CRITERIA  
6.2.1 Definitions  
For the purposes of this study, patients will be evaluated for response every 4 weeks.   
Response is defined by at least 50% reduction in TBSAI  at week 12 . 
Partial Response  is defined by 25 -49% reduction  in TBSAI  at week 12.  
No response to therapy is defined as stable or worsened (increase in total body surface area 
involvement) skin di sease on anakinra.  
40 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 Other parameters used to assess disease response include American College of Rheumatology 
criteria  and other clinical markers . ACR20/50/70 is defined as 20%, 50% and 70% improvement 
in tender or swollen joint counts , respectively.  
6.2.2 Disea se Parameters  
Measurable disease :  Total body surface area involvement of pustul es and erythematous plaques 
will be measured in this study. At the time of enrollment, all study participants will have active 
disease warranting systemic therapy, as defined b y macroscopic non -infective pustular and 
inflammatory skin lesions involving ≥ 5% of the total body surface area , or palmoplantar 
involvement.    
Joint involvement will also be assessed using criteria set forth by the American College of 
Rheumatology.  
6.2.3 Methods for Evaluation of Measurable Disease  
Plaque and pustular disease will  be measured by Total Body Surface Area Involvement (TBSAI) 
as well as Physician Global Assessment (PGA). Additionally, Pustular Psoriasis Assessment 
Severity Index (PPASI) and Palmoplantar Psoriasis Assessment Severity Index (P PPASI) scores 
will be calculated for each patient ( APPENDIX H: PUSTULAR DERMATOSIS CLINICAL 
ASSESSMENT SCALE ).  All baseline evaluations will be performed as closely as possible to 
the beginning of treatment and not more than 4 weeks before the be ginning of the treatment.  The 
same method of assessment and the same technique should be used to characterize skin l esion s at 
baseline and during follow -up.  
Clinical lesions :  Skin lesions will be documented using clinical examination and disposable 
ruler  as needed, and color photography  (at the investigator’s discretion) . Joint lesions will be 
documented by clinical examination as delineated by ACR guidelines, and joint imaging 
modalities . Ocular involvement will be assessed through a comprehensive ophtha lmic exam 
including assessment for keratoconjunctivitis. Ocular  exams will occur in the eye clinic at 
baseline and at completion of the study unless otherwise medically indicated.   Specialized 
ophthalmic testing (i.e., optical coherence tomography, fluore scein angiography, fundus photos 
or visual fields) will only be performed if   medically indicated and required to establish a 
diagnosis.  
Histology :  Histologic evaluation will be used to diagnose and characterize disease at the time of 
enrollment  and com pletion of anakinra .  
6.2.4 Response Criteria  
6.2.4.1  Evaluation of Target Lesions  
TBSAI 50 is defined as 50% improvement in total body surface area involvement.  
ACR20/50/70 is defined as 20%, 50% and 70% improvement in tender or swollen joint counts 
and other clinical m arkers, respectively.  
 
No response to therapy is defined as stable or worsened (increase in total body surface area 
involvement) skin disease on anakinra.  
41 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 7 SAFETY REPORTING REQ UIREMENTS/DATA AND S AFETY MONITORING 
PLAN  
7.1 DEFINITIONS  
7.1.1 Adverse Event  
Any untoward medical occurrence in a human subject, including a ny abnormal sign (for 
example, abnormal physical exam or laboratory finding), symptom, or disease, temporally 
associated with the subject’s participation in research, whether or not considered related to th e 
subject’s participation in the research .  
7.1.2 Suspected adverse reaction  
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the 
adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality 
than adverse reaction, which means any adverse event caused by a  drug.  
7.1.3 Unexpected adverse reaction  
An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in 
the investigator brochure or is not listed at the specificity or severity that has been observed; or, 
if an investigator bro chure is not required or available, is not consistent with the risk information 
described in the general investigational plan or elsewhere in the current application. 
"Unexpected” also refers to adverse events or suspected adverse reactions that are mentio ned in 
the investigator brochure as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are not specifically mentioned as occurring with the 
particular drug under investigation.  
7.1.4 Serious  
An Unanticipated Problem  or Protocol Deviation  is serious if it meets the defini tion of a Serious 
Adverse Event  or if it compromises the safety, welfare or rights of subjects or others.  
7.1.5 Serious Adverse Event  
An adverse event or suspected adverse reaction is considered serio us if in the view of the 
investigator or the sponsor, it results in any of the following:  
• Death  
• A life -threatening adverse drug experience  
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substan tial disruption of the ability to conduct 
normal life functions  
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered a serious adverse drug experience wh en, based upon 
42 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  
7.1.6 Disability  
A substantial disruption of a person’s ability to conduct normal life functions.  
7.1.7 Life-threatening adverse drug experience  
Any adverse event or suspected adverse reaction  that places the patient or subject, in the view of 
the investigator  or sponsor , at immediate risk of death from the reaction as it occur red, i.e., it 
does not include a reaction that had it occurred in a more severe form, might have caused death.  
7.1.8 Protocol Deviation (NIH Definition)  
Any change, divergence, or departure from the IRB -approved research protocol . 
7.1.9 Non-compliance  (NIH Definition)  
The failure to comply with applicable NIH Human Research Protections Program ( HRPP ) 
policies, IRB requirements, or regulatory requirements for the protection of human research 
subjects . 
7.1.10  Unanticipated Problem  
Any incident , experience, or outcome that : 
•  Is unexpected in terms of nature, severity, or frequency in relation to  
(a) the research risks that are described in the IRB -approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents, and  
(b) the characteristi cs of the subject population being studied; AND  
• Is related or possibly related to participation in the research; AND  
• Suggests that research places subjects or others at a g reater risk of harm  (including 
physical, psychological, economic, or social harm) th an was previously known or 
recognized.  
7.2 NIH  INTRAMURAL  IRB  AND CLINICAL DIRECTOR REPORTING   
7.2.1 NIH Intramural  IRB and NCI CD Expedited Reporting of Unanticipated Problems  and 
Deaths  
The Protocol PI will report in the NIH Problem Form to the NIH Intramural  IRB and NCI 
Clinical Director : 
• All deaths, except deaths due to progressi ve disease   
• All Protocol Deviations  
• All Unanticipated Problems  
• All non -compliance  
Reports must be received within 7 days of PI awareness via iRIS.  
43 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 7.2.2 NIH Intramur al IRB Requirements for PI Reporting at Continuing Review  
The protocol PI will report to the NIH Intramural  IRB:  
1. A summary of all protocol deviations in a tabular format to include the date the deviation 
occurred, a brief description of the deviati on and any corrective action.  
2. A summary of any instances of non -compliance  
3. A tabular summary of the following adverse events:  
• All Grade 2 unexpected  events that  are possibly, probably or definitely related to the 
research;  
• All Grade 3 and 4 events that ar e possibly, probably or definitely related to the 
research;  
• All Grade 5 events regardless of attribution;  
• All Serious Events regardless of attribution.  
NOTE : Grade 1 events are not required to be reported.  
7.3 NCI Guidance for Reporting Expedited Adverse E vents for Multi -Center Trials   
The site PI must immediately report to the coordinating center PI any serious adverse event, 
whether or not considered drug related, including those listed in the protocol or investigator 
brochure and must include an assessme nt of whether there is a reasonable possibility that the 
drug caused the event within 24 hours of PI awareness of the event.  The Site PI must also report 
any protocol deviations to the coordinating center PI within 7 days of PI awareness  using t he 
problem  report form (See APPENDIX L: CCR PROBLEM REPORT FORM ). A copy of this 
form can also be obtained from the NIAMS study coordinator.  Participating centers must also 
submit the report to their IRB in accordance with their institutional policies.  
7.4 DATA AND SAFETY MONITORING PLAN 
7.4.1 Principal Investigator/Research Team  
The clinical research tea m will meet weekly  when patients are being actively treated on the trial 
to discuss each patient. Decisions about dose level enroll ment and dose escalation if applicable 
will be made based on the toxicity data from prior patients.  
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. Adverse events will be reported as required above. Any safety concerns, 
new information that might affect either the ethical and or scientific conduct of the trial, or 
protocol deviations will be immediately reported to the IRB using iRIS .  
The principal investigator will review adverse event and response data on each patient to ensure 
safety and data accuracy. The principal investigator will personally conduct or supervise the 
investigation and provide appropriate delegation of responsibilities to other m embers of the 
research staff.  
44 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 7.4.2 Safety Monitoring Committee (SMC)  
This protocol will require oversight from the Safety Monitoring Committee (SMC).  Initial 
review will occur as soon as possible after the annual NIH Intramural  IRB continuing review 
date.   Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting 
schedule permits or more frequently as may be required by the SMC.  For initial and subsequent 
reviews, protocols will not be reviewed if there is no accrual w ithin the review period. Written 
outcome letters will be generated in response to the monitoring activities and submitted to the 
Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.  
8 STATISTICAL CONSIDERATIONS    
The primary o bjective of this one-stage phase 2 study is to obtain an estimate of the response rate 
to treatment with anakinra for pustular dermatoses. Those patients who experience at least a 50% 
improvement in TBSAI will be considered responders. With 25 evaluable pa tients, the maximum 
width of a two -sided 95% confidence interval will be +/ -20% if the response rate is 50%, and less 
wide if the response rate is either lower or higher than 50%. An early stopping rule will be 
implemented  in order to guard against undue r isk to enrolled subjects . If 0 of the first 9 patients  
fail to respond to anakinra therapy, there is a 95% probabi lity that the true response rat e is 28% 
or less, which is unacceptably low , and we will halt further patient recruitment.  
All other biologic p arameters will be evaluated using exploratory and descriptive methods, 
emphasizing non -parametric techniques.  
It is anticipated that 1 -2 patients per month may enroll onto this trial. In order to allow for a 
small number of unevaluable patients, the accrua l ceiling will be set at 30 patients. Accrual 
would be estimated to last 18 -24 months in order to enroll up to 30 patients.   
9 COLLABORATIVE AGREEM ENTS   
9.1 AGREEMENT TYPE 
9.1.1 Clinical Trials Agreement  
Clinical Trials Agreement (CTA) # 924 has been executed for the transfer of anakinra from 
Biovitrum to NCI.  
9.1.2 Material Transfer Agreement  
A Material Transfer Agreement will be executed with Hailey Naik/ University of California, San 
Francisco for the transfer of blood specimens and patient data.  
9.2 MULTI -INSTITUTIONAL GUIDE LINES  
9.2.1 IRB Approvals  
The PI will provide the NIH Intramural  IRB with a copy of the participating institution’s 
approved yearly continuing review.  Registration will be halted at any participating institution in 
which a current continuing approval is  not on file at the NIH Intramural  IRB. 
45 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 9.2.2 Amendments and Consents  
The NIAMS  PI will provide the NIH Intramural  IRB with copies of all amendments, consents 
and approvals from each participating institution.  
10 HUMAN SUBJECTS PROTE CTIONS  
10.1 RATIONALE FOR SUBJECT SELECTION  
Subjects who have inflammatory pustular skin diseases will be enrolled. The gender, age and 
ethnic distribution is expected to represent the characteristics of the patients genetically 
predisposed to developing these conditions. This protocol intends to enroll an appropriately 
balanced study population consistent with the distribution of these diseases. No sex or 
racial/ethnic group will be specifically recruited or excluded for this study.   
10.2 PARTICIPATION OF CHILDREN  
Individuals under the age of 18 will not be eligible to participate in this study at this time  due to 
discomfort of multiple injections and dose escalation nature of the study as well as  the unknown 
safety of higher than FDA approved doses in children . 
10.3 PARTICIPATION OF NIH  SUBJECTS UNABLE TO GIVE CONSENT  
Adults unable to give consent are ex cluded from enrolling in the protocol.  However re -consent 
may be ne cessary and there is a possibility, though unlikely, that subjects could become 
decisionally impaired. For this reason a nd because there is a prospect of direct benefit from 
research participation  (section  10.5), all subjects  will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute de cision maker on the “NIH Advance 
Directive for Health Care and Medical Research Participation” form so that another person can 
make decisions  about their medical care in the event that they become incapacitated or 
cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH 
Ability to Consent Assessment Team (ACAT) for evaluation  as needed for the following: an 
independent assessment of whether an individual has the capacity to provide consent; assistance 
in identifying and a ssessing an appropriate surrogate when indicated; and/or an assessment of the 
capacity to appoint a surrogate . For those subjects that become incapacitated and do not have 
pre-determined substitute decision maker, the procedures described in MAS Policy 87 -4 and 
NIH HRPP SOP 14E for appointing a surrogate decision maker for adult subjects who are (a) 
decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, 
will be followed.  
10.3.1  For Participating Sites  
Participating sites shou ld follow local procedures regarding re -consent for subjects that become 
decisionally impaired.  
10.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
Subjects participating in this protocol may potentially benefit from an improvement in symptoms 
of neutrophilic pus tular dermatosis.  Potential risks include the range of side effects listed in 
46 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 section  11.1.2 .  Subjects will be evaluated medically throughout the protocol in order to 
minimize risk.   
 
Blood Sampling  
Side effe cts of blood draws include pain and bruising, lightheadedness, and rarely, fainting.  
 
Tissue Biopsy  
All care will be taken to minimize risks that may be incurred by tissue sampling.  However, there 
are procedure -related risks (such as bleeding, infection a nd scarring ) that will be explained fully 
during informed consent.   If patients suffer any physical injury as a result of the biopsies, 
medical treatment is available at the NIH’s Clinical Center in Bethesda, Maryland  or other 
participating site .  Although  no compensation is available, any injury will be fully evaluated and 
treated in keeping with the benefits or care to which patients are entitled under applicable 
regulations.  
 
10.5 RISKS/BENEFITS ANALYSIS  
Inflammatory p ustular dermatoses are associated with si gnificant morbidity and mortality. 
Patients  with generalized skin disease are subject to risk  of infection. Many of the pustular 
dermatoses are refractory to currently -available therapies which fail to mitigate disease course 
and complications.  Randomized  controlled trials have not been undertaken due to rarity of 
disease and cost of such a study.  An effective therapeutic agent for the management of this 
group of diseases would be both a significant contribution to clinical management and to our 
understan ding of pathogenesis of neutrophilic and pustular disease.  Based on current scientific 
knowledge, IL -1 plays a key role in pathogenesis of neutrophilic and pustular diseases.   IL-1 
antagonist a nakinra has been safely and successfully used in children with  autoinflammatory 
diseases including NOMID and DIRA, and we anticipate the drug will be similarly well -tolerated 
in adults  with pustular diseases.  We anticipate this study will be associated with more than 
minimal risk  and offers the prospect of direct be nefit due to protocol treatment for adult subjects, 
including those who are or may become unable to consent .  
10.6 CONSENT PROCESS AND DOCUMENTATION  
Patients will meet with an associate or principal investigator on the trial in the NIH Dermatology  
Clinic or par ticipating site clinic during the initial evaluation for this study.  During that meeting, 
the investigator will inform patients of the purpose, alternatives, treatment plan, research 
objectives and follow -up of this trial.  The investigator will then prov ide a copy of the IRB -
approved informed consent document that is included in this protocol.  The patient will be 
allowed to take as much time as he wishes, in deciding whether or not he wishes to participate.  
If a prolonged period of time expires during t he decision -making process (several weeks, as an 
example), it may be necessary to reassess the patient for protocol eligibility.  Subjects will 
consent to procedures performed at the investigator’s discretion (biopsy, PET scan, CT scan, 
MRI scan) at the ti me of the procedure. If the subject  refuses the optional procedure  at that time, 
the refusal will be documented in the medical record and in the research record. The original 
signed consent s go to Medical Records; and a copy of each will be placed in the research record 
(NIH policy).  
47 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 All patients must have a signed informed consent form and an on -study (confirmation of 
eligibility) form filled out and signed by a participating investigator before entering on the study . 
10.6.1  Telephone Reconsent  
Reconsent on this study may be obtained via telephone according to the following procedure: the 
informed consent document will be sent  to the subject.   An explanation of the change (s) in the 
study will be provided over the telephone after the subject has had the opportunit y to read the 
consent form.   The subject will sign and date the informed consent. A witness  to the subject’s 
signature will sign and date the consent.   
The original informed consent document will be sent back to the consenting investigator who 
will sign an d date the consent form with the date the consent was obtained via telephone.   
A fully executed copy will be returned via mail for the subject’s records.    
The informed consent process will be documented on a progress note by the consenting 
investigator.  
10.6.2  Informed consent of non -English speaking subjects  
If there is an unexpected enrollment of a research participant for whom there is no translated 
extant IRB approved consent document, the principal investigator and/or those authorized to 
obtain informed con sent will use the Short Form Oral Consent Process as described in MAS 
Policy M77 -2, OHSRP SOP 12, 45 CFR 46.117 (b) (2).  The summary that will be used is the 
English version of the extant IRB approved consent document.  Signed copies of both the 
English v ersion of the consent and the translated short form will be given to the subject or their 
legally authorized representative and the signed original will be filed in the medical record.  
Unless the PI is fluent in the prospective subject’s language, an inter preter will be present to 
facilitate the conversation. Preferably someone who is independent of the subject (i.e., not a 
family member) will assist in presenting information and obtaining consent. Whenever possible, 
interpreters will be provided copies of the relevant consent documents well before the consent 
conversation with the subject (24 to 48 hours if possible).  
We request prospective IRB approval of the use of the short form process for non -English 
speaking subjects and will notify the IRB at the ti me of continuing review of the frequency of the 
use of the Short Form.  
11 PHARMACEUTICAL INFOR MATION   
11.1 ANAKINRA  
Please refer to package insert for complete information . This protocol is exempt from an IND in 
accordance with Title 21 of the Code of Federal Reg ulations, Part 312.2 (b)  as it meets all of the 
following exemption criteria:  
1. The investigational drug is lawfully marketed in the United States . 
2. The investigation is not intended to be reported to the FDA as a well -controlled study in 
support of a new ind ication for use of the drug product.  
48 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 3. The investigation is not intended to support a significant change in advertising to an 
existing lawfully marketed prescription drug product.  
4. The investigation does not involve a route of administration or dosage level o r use in a 
patient population or other factor that significantly increases the risks (or decreases the 
acceptability of the risks) associated with the use of the drug product.  
5. The investigation will be conducted in compliance with the requirements for inst itutional 
review set forth in FDA regulations 21 CFR 56, and requirements for informed consent 
as set forth in FDA regulations 21 CFR 50.  
11.1.1  Source:  Biovitrum   
Anakinra will be donated by the manufacturer . Anakinra may also be  purchased directly through  
the N IH pharmacy  for NIH patients . 
11.1.2  Toxicity  
The safety and efficacy of anakinra have been evaluated in 3 randomized, double -blind, placebo -
controlled trials of 1392 patients 18 years of age with active RA42.  An ad ditional fourth study 
was conducted to assess drug safety.  
 
Injection -site Reactions  
The most common and consistently reported treatment -related adverse event associated with 
anakinra is injection -site reaction (ISR). Seventy -one percent of patients develo ped an ISR, 
which was typically reported within the first 4 weeks of therapy in clinical trials.   The majority 
of ISRs were reported as mild (72.6% mild, 24.1% moderate and 3.2% severe).  The ISRs 
typically lasted for 14 to 28 days and were characterized b y 1 or more of the following: 
erythema, ecchymosis, inflammation, and pain.  
Infections  
In placebo -controlled trials , the inciden ce of infection was 39% in the a nakinra -treated patients 
and 37% in placebo -treated patients during the first 6 months of blind ed treatment.  The 
incidence of serious infections in Studies 1 and 4 was 2% in anakinra -treated patients and 1% in 
patients receiving placebo over 6 months.  The incidence of serious infection over 1 year was 3% 
in anakinra -treated patients and 2% in pati ents receiving placebo.  These infections consisted 
primarily of bacterial events such as cellulitis, pneumonia, and bone and joint infections.  The 
majority of patients (73%) continued on study drug after the infection resolved.  No serious 
opportunistic infections were reported.  Patients with asthma appeared to be at higher risk of 
developing serious infections when treated with anakinra (8 of 177 patients, 4.5%) compared to 
placebo (0 of 50 patients, 0%).  
In open -label extension studies, the overall rat e of serious infections was stable over time and 
comparable to that observed in controlled trials.  In clinical studies and post  marketing 
experience, cases of opportunistic infections have been observed and included fungal, 
mycobacterial and bacterial pat hogens.  Infections have been noted in all organ systems and have 
been reported in patients receiving anakinra alone or in combination with immunosuppressive 
agents.  
49 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 In patients who received both anakinra and etanercept for up to 24 weeks, the incidence of  
serious infections was 7%.  The most common infections consisted of bacterial pneumonia (4 
cases) and cellulitis (4 cases).  One patient with pulmonary fibrosis and pneumonia died due to 
respiratory failure.  
Malignancies  
Among 5300 RA patients treated wit h anakinra in clinical trials for a mean of 15 months 
(approximately 6400 patient years of treatment), 8 lymphomas were observed for a rate of 0.12 
cases/100 patient years.  This is 3.6 fold higher than the rate of lymphomas expected in the 
general populat ion, based on the National Cancer Institute's Surveillance, Epidemiology a nd End 
Results (SEER) database.   However, reports indicate that the  rate of lymphoma  is doubled in the 
rheumatoid arthritis  (RA) population, and may be further increased in patients with more severe 
disease activity47, 48.  Thirty -seven malignancies other than lymphoma were observed.  Of these, 
the most common were breast, respiratory system, and digestive system.   There were 4 
melanomas observ ed in one study and its long -term open -label extension , however these cases 
were not thought to be related to anakinra . The significance of this finding is not known.  While 
patients with RA, particularly those with highly active disease, may be at a highe r risk (up to 
several -fold) for the development of lymphoma, the role of IL -1 blockers in the development of 
malignancy is not known.  
Hematologic Events  
In placebo -controlled studies with anakinra, 8% of patients receiving anakinra had a decrease in 
total white blood counts of at least one WHO toxicity grade, compared with 2% of placebo 
patients.  Nine anakinra -treated patients (0.4%) developed neutropenia (ANC < 1 x 109/L).  Nine 
percent  of patients receiving anakinra had increases in eosinophil differenti al percentage of at 
least one WHO toxicity grade, compared with 3 % of placebo patients.  Of patients treated 
concurrently with anakinra and etanercept , 2% developed neutropenia (ANC < 1 x 109/L).  One 
neutropenic patient developed cellulitis and recovered  with antibiotic therapy.  Two percent  of 
patients receiving anakinra had decrease d platelets, all of WHO toxicity grade one, compared to 
0% of placebo patients.  
Hypersensitivity Reactions  
Hypersensitivity reactions including anaphylactic reactions, angioe dema, urticaria, rash, and 
pruritus have been reported with anakinra.  
Immunogenicity  
In placebo -controlled studies , from which data is available for up to 36 months, 49% of patients 
tested positively at one or more time  points for anti -anakinra antibodies in a highly sensitive, 
anakinra -binding biosensor assay.  Of the 1615 patients with available data at Week 12 or later, 
30 (2%) were seropositive in a cell -based bioassay for antibodies capable of neutralizing the 
biologic effects of Anakinra.  Of the 13 p atients with available follow -up data, 5 patients 
remained positive for neutralizing antibodies at the end of the studies.  No correlation between 
antibody development and adverse events was observed.  
Antibody assay results are highly dependent on the sens itivity and specificity of the assays.  
Additionally, the observed incidence of antibody positivity in an assay may be influenced by 
several factors, including sample handling, concomitant medications, and underlying disease.  
50 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 For these reasons, comparison  of the incidence of antibodies to anakinra with the incidence of 
antibodies to other products may be misleading.  
Other Adverse Events  
Other adverse events that occurred at similar rate to placebo included: URI, sinusitis, influenza 
like symptom, headache , nausea, diarrhea, sinusitis and abdominal pain.  
Overdosage  
There have been no cases of overdose reported with anakinra  in clinical trials of rheumatoid 
arthritis.  In sepsis trials, no serious toxicities attributed to anakinra  were seen when administere d 
at mean calculated doses of up to 35 times those given patients with RA over a 72 -hour treatment 
period.  
Experience in NOMID  
In addition to the adverse events described in the package insert, our center has considerable 
experience in treating NOMID pati ents with anakinra.  Our cohort of primarily pediatric patients 
has been treated with anakinra doses ranging from 1 mg/kg to 6.7 mg/kg daily.  This practice is 
consistent with that of other specialty centers where doses as high as 10 mg/kg daily were used 
to control disease in the treatment of NOMID65.  In our experience with 26 patients and 1494 
patient -years (an average of 57.5 months / patient), the most frequently observed adverse events 
were upper res piratory infections 88.5%, gastroenteritis 46.2%, otitis media 38.5%, injection site 
reactions 34.6%, urinary tract infections 23.1%, transient transaminase elevation 15.4%, 
epistaxis 15.4%, otitis externa 11.6%, cellulitis 11.6%, and pneumonia 7.7%.  One patient had an 
episode of viral meningitis, one had a catheter infection, and one had a recurrent bowel 
abscesses.  Serious adverse events during this period included an ICU admission to evaluate for a 
post lumbar puncture bleed at 1 mg/kg/day, a wound inf ection with surrounding cellulitis at 3 
mg/kg/day, and macrophage ac tivation syndrome at 2 mg/ kg/day.   None of the adverse events 
required discontinuation of anakinra.  In a cohort of 10  French NOMID patients treated with 
anakinra described with follow -up ranging from three months to twenty years, the only reported 
adverse events were injection site reactions65. 
11.1.3   Formulation and preparation  
Anakinra is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, 
clear, colorless -to-white, preservative free solution for daily subcutaneous (SC) administration.  
The solution may contain trace amounts of small, translucent -to-white amorphous proteinaceous 
particles.  Each prefilled glass  syringe contains: 0.67 mL (100 mg) of anakinra in a solution (pH 
6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), 
and polysorbate 80 (0.70 mg) in Water for Injection, USP.  
11.1.4   Stability and Storage  
Anakinra shoul d not be shaken.   Before using, the product should be checked visually for 
particles or discoloration.  If either is present, the liquid  should not be used .  The medication 
should be warm ed to room temperature for 60 t o 90 minutes before injecting .  
11.1.5  Admini stration procedures  
This medication is injected subcutaneously once a day.  
51 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 Before injecting each dose, the injection site should be cleaned with rubbing alcohol.  It is 
important to change the location of the injection site daily.  The medication should not be 
inject ed into an area that is tender, red, bruised, or hard or which has scars or stretch marks.   
11.1.6   Incompatibilities  
No drug -drug interaction studies in human subjects have been conducted.  Toxicologic and 
toxicokinetic studies in rats did not demo nstrate any alterations in the clearance or toxicologic 
profile of either methotrexate or anakinra when the two agents were administered together.  
TNF Blocking Agents: A higher rate of serious infections has been observed in patients treated 
with concurren t anakinra and etanercept therapy than in patients treated with etanercept alone. 
Two percent of patients treated concurrently with anakinra and etanercept developed neutropenia 
(ANC<  1x109/L). Use of anakinra in combination with TNF blocking agents is not  
recommende d and use of TNF blocking agents is an exclusion criterion  for study entry . 
52 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 12 REFERENCES  
 
1. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with 
deficiency of the interleukin -1-receptor antagonis t. N Engl J Med 2009;360:2426 -37. 
2. Jesus AA, Osman M, Silva CA, et al. A novel mutation of IL1RN in the deficiency of 
interleukin -1 receptor antagonist syndrome: description of two unrelated cases from Brazil. 
Arthritis Rheum 2011;63:4007 -17. 
3. Jesus AA S, Clovis Artur Almeida; Kim, Peter W.; Pham, Tuyet H.; Bertola, Débora 
Romeo; Carneiro -Sampaio, Magda. Novel Founder Mutation in IL1RN Accounts for Deficiency 
of the IL -1 Receptor (DIRA) in Brazil. Arthritis Rheum 2010;62:260.  
4. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous 
deletion of the IL1RN locus. N Engl J Med 2009;360:2438 -44. 
5. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin -36-receptor antagonist deficiency 
and generalized pustular psoriasis. N Engl J Med 2011;365:620 -8. 
6. Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated 
with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am 
J Hum Genet 2011;89:432 -7. 
7. Viguier M, Guigue P, Pages C , Smahi A, Bachelez H. Successful treatment of 
generalized pustular psoriasis with the interleukin -1-receptor antagonist Anakinra: lack of 
correlation with IL1RN mutations. Ann Intern Med 2010;153:66 -7. 
8. Albanesi C, Scarponi C, Giustizieri ML, Girolomoni  G. Keratinocytes in inflammatory 
skin diseases. Curr Drug Targets Inflamm Allergy 2005;4:329 -34. 
9. Tschachler E. Psoriasis: the epidermal component. Clin Dermatol 2007;25:589 -95. 
10. Lutz V, Lipsker D. Acitretin - and tumor necrosis factor inhibitor -resistant acrodermatitis 
continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch 
Dermatol 2012;148:297 -9. 
11. Piskin G, Sylva -Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of 
IL-23 by keratinocytes in healt hy skin and psoriasis lesions: enhanced expression in psoriatic 
skin. J Immunol 2006;176:1908 -15. 
12. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by 
TNF inhibition is associated with reduced Th17 responses. J Exp Med 2 007;204:3183 -94. 
13. Kolls JK, Linden A. Interleukin -17 family members and inflammation. Immunity 
2004;21:467 -76. 
14. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in 
humans. J Clin Endocrinol Metab 2007;92:2272 -9. 
15. McGill icuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse 
cholesterol transport in vivo. Circulation 2009;119:1135 -45. 
16. Mehta NN, McGillicuddy FC, Anderson PD, et al. Experimental endotoxemia induces 
adipose inflammation and insulin resistance in humans. Diabetes 2010;59:172 -81. 
17. Shah R, Lu Y, Hinkle CC, et al. Gene profiling of human adipose tissue during evoked 
inflammation in vivo. Diabetes 2009;58:2211 -9. 
18. Heffron SP, Parastatidis I, Cuchel M, et al. Inflammation induces fib rinogen nitration in 
experimental human endotoxemia. Free Radic Biol Med 2009;47:1140 -6. 
53 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 19. Alexander ET, Vedhachalam C, Sankaranarayanan S, et al. Influence of apolipoprotein 
A-I domain structure on macrophage reverse cholesterol transport in mice. Arter ioscler Thromb 
Vasc Biol 2011;31:320 -7. 
20. Khera AV, Cuchel M, de la Llera -Moya M, et al. Cholesterol efflux capacity, high -
density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127 -35. 
21. Basu S, Zaidi H, Houseni M, et al. Novel quant itative techniques for assessing regional 
and global function and structure based on modern imaging modalities: implications for normal 
variation, aging and diseased states. Semin Nucl Med 2007;37:223 -39. 
22. Bural GG, Torigian DA, Chamroonrat W, et al. Qu antitative assessment of the 
atherosclerotic burden of the aorta by combined FDG -PET and CT image analysis: a new 
concept. Nucl Med Biol 2006;33:1037 -43. 
23. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with 
moderate to severe psoriasis as measured by [18F] -fluorodeoxyglucose positron emission 
tomography -computed tomography (FDG -PET/CT): a pilot study. Arch Dermatol 
2011;147:1031 -9. 
24. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission 
tomogra phy imaging of atherosclerotic plaque inflammation is highly reproducible: implications 
for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892 -6. 
25. Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Noninvasive detection 
and localizati on of vulnerable plaque and arterial thrombosis with computed tomography 
angiography/positron emission tomography. Circulation 2008;117:2061 -70. 
26. Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascular 18F -FDG 
uptake with plasma high -densit y lipoprotein elevation by atherogenic risk reduction. J Nucl Med 
2008;49:1277 -82. 
27. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET 
imaging in stable cancer disease patients indicates higher risk for cardiovascular  events. J Nucl 
Cardiol 2008;15:209 -17. 
28. Rominger A, Saam T, Wolpers S, et al. 18F -FDG PET/CT identifies patients at risk for 
future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 
2009;50:1611 -20. 
29. Tahara N, K ai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: 
evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 
2006;48:1825 -31. 
30. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL -1 in tumorigenesis, tumor  
invasiveness, metastasis and tumor -host interactions. Cancer Metastasis Rev 2006;25:387 -408. 
31. Voronov E, Shouval DS, Krelin Y, et al. IL -1 is required for tumor invasiveness and 
angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645 -50. 
32. Humbert P, Bl anc D, Laurent R, Agache P. Monoclonal IgG gammopathy in a case of 
pustular psoriasis. A ten year follow -up. Blut 1987;54:61 -2. 
33. Reed J, Wilkinson J. Subcorneal pustular dermatosis. Clin Dermatol 2000;18:301 -13. 
34. Fisher CJ, Jr., Dhainaut JF, Opal SM,  et al. Recombinant human interleukin 1 receptor 
antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double -
blind, placebo -controlled trial. Phase III rhIL -1ra Sepsis Syndrome Study Group. JAMA 
1994;271:1836 -43. 
35. Fisher CJ, Jr., Opal SM, Lowry SF, et al. Role of interleukin -1 and the therapeutic 
potential of interleukin -1 receptor antagonist in sepsis. Circ Shock 1994;44:1 -8. 
54 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 36. Fisher CJ, Jr., Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant 
interleukin -1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open -label, 
placebo -controlled multicenter trial. Crit Care Med 1994;22:12 -21. 
37. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a 
recombinan t human interleukin -1 receptor antagonist, in combination with methotrexate: results 
of a twenty -four-week, multicenter, randomized, double -blind, placebo -controlled trial. Arthritis 
Rheum 2002;46:614 -24. 
38. Cohen SB, Moreland LW, Cush JJ, et al. A multic entre, double blind, randomised, 
placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in 
patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 
2004;63:1062 -8. 
39. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human 
interleukin -1 receptor antagonist (r -metHuIL -1ra), in patients with rheumatoid arthritis: A large, 
international, multicenter, placebo -controlled trial. Arthritis Rheum 2003;48:927 -34. 
40. Fleis chmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra 
in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006 -12. 
41. Nuki G, Bresnihan B, Bear MB, McCabe D. Long -term safety and maintenance of 
clinical improvement fol lowing treatment with anakinra (recombinant human interleukin -1 
receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, 
double -blind, placebo -controlled trial. Arthritis Rheum 2002;46:2838 -46. 
42. Oaks AT. Kineret Physi cian Package Insert. In: Manufacturing A, ed.; 2001 -2003.  
43. Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo 
case of neonatal -onset multisystem inflammatory disease. Arthritis Rheum 2004;50:2708 -9. 
44. Hawkins PN, Lachmann H J, Aganna E, McDermott MF. Spectrum of clinical features in 
Muckle -Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607 -12. 
45. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response 
to anakinra in 22 patients  with autoinflammatory disease associated with CIAS -1/NALP3 
mutations. Arch Dermatol 2006;142:1591 -7. 
46. Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid 
arthritis. BioDrugs 2005;19:189 -202. 
47. Askling J, Fored CM, Baecklu nd E, et al. Haematopoietic malignancies in rheumatoid 
arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. 
Annals of the rheumatic diseases 2005;64:1414 -20. 
48. Baecklund E, Iliadou A, Askling J, et al. Associ ation of chronic inflammation, not its 
treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis & Rheumatism 
2006;54:692 -701. 
49. Gomez -Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of 
rheumatoid arthritis with tumor ne crosis factor inhibitors may predispose to significant increase 
in tuberculosis risk: a multicenter active -surveillance report. Arthritis Rheum 2003;48:2122 -7. 
50. Askling J, Dixon W. The safety of anti -tumour necrosis factor therapy in rheumatoid 
arthriti s. Curr Opin Rheumatol 2008;20:138 -44. 
51. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double -blind, 
placebo -controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis 
factor -alpha, in patients with moder ate-to-severe heart failure: results of the anti -TNF Therapy 
Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133 -40. 
55 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 52. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and 
anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740 -51. 
53. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti -tumor 
necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862 -9. 
54. Shakoor N, Mich alska M, Harris CA, Block JA. Drug -induced systemic lupus 
erythematosus associated with etanercept therapy. Lancet 2002;359:579 -80. 
55. Fuentes -Duculan J, Suarez -Farinas M, Zaba LC, et al. A subpopulation of CD163 -
positive macrophages is classically activa ted in psoriasis. J Invest Dermatol 2010;130:2412 -22. 
56. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF -alpha and inducible nitric 
oxide synthase -expressing dendritic cells in psoriasis and reduction with efalizumab (anti -
CD11a). Proc Natl Acad Sc i U S A 2005;102:19057 -62. 
57. Haider AS, Cohen J, Fei J, et al. Insights into gene modulation by therapeutic TNF and 
IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF -regulated 
genes linked to psoriasis transcriptome. J Invest Derm atol 2008;128:655 -66. 
58. Suarez -Farinas M, Fuentes -Duculan J, Lowes MA, Krueger JG. Resolved psoriasis 
lesions retain expression of a subset of disease -related genes. J Invest Dermatol 2011;131:391 -
400. 
59. Zaba LC, Suarez -Farinas M, Fuentes -Duculan J, et  al. Effective treatment of psoriasis 
with etanercept is linked to suppression of IL -17 signaling, not immediate response TNF genes. J 
Allergy Clin Immunol 2009;124:1022 -10 e1 -395. 
60. Bural GG, Torigian DA, Chamroonrat W, et al. FDG -PET is an effective im aging 
modality to detect and quantify age -related atherosclerosis in large arteries. Eur J Nucl Med Mol 
Imaging 2008;35:562 -9. 
61. Chen W, Bural GG, Torigian DA, Rader DJ, Alavi A. Emerging role of FDG -PET/CT in 
assessing atherosclerosis in large arteries.  Eur J Nucl Med Mol Imaging 2009;36:144 -51. 
62. Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are 
efficiently immortalized by a Rho kinase inhibitor. J Clin Invest 2010;120:2619 -26. 
63. Steude J, Kulke R, Christophers E. Interleuk in-1-stimulated secretion of interleukin -8 and 
growth -related oncogene -alpha demonstrates greatly enhanced keratinocyte growth in human raft 
cultured epidermis. J Invest Dermatol 2002;119:1254 -60. 
64. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K,  Yuspa SH. Calcium 
regulation of growth and differentiation of mouse epidermal cells in culture. Cell 1980;19:245 -
54. 
65. Hazarika D. Generalized pustular psoriasis of pregnancy successfully treated with 
cyclosporine. Indian J Dermatol Venereol Leprol 2009 ;75:638.  
 
 
56 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 13 APPENDIX A: FORBIDDEN DRUGS  
 
Abata cept/Orencia  
Adalimumab /Humira  
Alefacept /Amevive  
Canakinumab /Ilaris  
Certolizumab /Cimzia  
Etanercept /Enbrel  
Golimumab/Simponi  
Infliximab /Remicaide  
Rilonacept /Arcalyst  
Rituximab /Rituxan  
Phototherapy  
Live vaccines  
 
 
 
 
 
Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
 14 APPENDIX B: PATIENT D IARY   
 
PUSTULAR DERMATOSIS DIARY
Rate the symptoms from 0-3 to best describe the severity of the symptoms listed below
0=no symptoms
1=mild symptoms
2=moderate symptoms
3=severe symptoms (worst symptom observed)
Overall-well being (0=poor, 1=fair, 2=good, 3=excellent)
Please list name of study drug: anakinra
Please list all steroid medications here: 
Please list other immunosuppressive medications here: 
Dilute bleach baths/hibiclens wash? Yes or No
Day DateTime 
Anakinra 
dose given Fever Rash Pustules Itching Skin pain Joint painOverall      well-
beingDilute bleach bath/ 
hibiclens wash?
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31Fever: list the actual temperature in degress farenheit
 
Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
 15 APPENDIX C: PATIEN T HANDOUT  
 
Where can I inject anakinra/Kineret®?  
Upper arm  
Abdomen  
Thigh  
 
Remember  to rotate the injection site daily.  
 
 
 
 
 
 
 
Abbreviated Title:  Anakinra  in pustular dermatoses  
Version Date: December 12 , 2018 
 16 APPENDIX  D: DOSE MODIFICATION FLOW CHART  

60 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 17 APPENDIX E: SHORT FORM  36 (ENGLISH AND SPANISH)   
 
 
 
 
 
 
61 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
  
 
 
 
 
 
 
 
 
 
62 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  
  
 
 
 
 
 
 
 
63 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
 
 
 
64 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
  
 
 
 
 
 
 
65 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
 
 
 
 
 
Collection of this information is authorized under 42 USC 285. The primary use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and researchers for research purposes and to m onitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary.  
 
 
 
 
 
 
 
 
 
66 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

67 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

68 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

69 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

70 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

71 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
La recopilación de esta información está utorizada bajo el Código de los Estados Unidos, número 
42 USC 285. La información que us ted proporcione será usada principalmente para evaluar su 
salúd y calidad de vida. Esta informatción podria ser compartida con doctores e investigadores 
para fines de investigación o con monitores para garantizar que se mantengan las normas de 
seguridad.  El proveer esta información es voluntario.  
72 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 

73 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
 
74 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 18 APPENDIX F: DERMATOLOGY LIFE QUALITY (ENGLISH AND SPANISH)  
 
Collection of this information is authorized under 42 USC 285. The primary use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and researchers for research purposes and to monitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary.  
75 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 CUESTIONARIO  SOBRE LA CALIDAD DE VIDA – DERMATOLOGÍA  
 
El objetivo de este cuestionario consiste en determinar qué efecto ha tenido su problema de la piel en su 
vida DURANTE LA ÚLTIMA SEMANA.  Por favor marque con una “X” una casilla para cada pregunta.  
 
1. Durante la ú ltima semana, ¿ha sentido 
picazón , dolor  o ardor  en la piel o la ha tenido 
adolorida ? Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
   
2. Durante la última semana, ¿se ha sentido 
avergonzado/a  o cohibido/a  debido a su piel?  Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
   
3. Durante la última semana, ¿le ha molestado 
su condición de la piel para hacer las compras  
u ocuparse de la casa  o el jardín ? Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relación   
 
 
 
4. Durante la última semana, ¿ha influido su 
condición de la piel e n la elección de la ropa 
que lleva?  Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relación   
 
 
 
 
5. Durante la última semana, ¿ha influido su 
condición de la piel en alguna actividad social  
o recreativa ? Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relació n  
 
 
 
6. Durante la última semana, ¿ha tenido 
dificultad para practicar deportes  debido a su 
condición de la piel?  Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relación   
 
 
 
7. Durante la última semana, ¿le ha impedido su 
condición de la piel trabajar  o estudiar ? 
 Sí 
No  
 
  
Sin relación   
 
 
 Si la respuesta es "No", durante la última 
semana, ¿cuánta dificultad le ha ocasionado 
su condición de la piel en el trabajo  o en sus 
estudios ? Mucho  
Un poco  
Nada  
  
 
   
 
8. Durante la última semana, ¿su condic ión de 
la piel le ha ocasionado dificultades con su 
pareja , amigos íntimos  o familiares ? Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relación   
 
 
 
9. Durante la última semana, ¿cuánta dificultad 
le ha ocasionado su condición de la piel en Muchísimo  
Mucho   
  
  
 
76 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 su vida sexual ? Un poco  
Nada  
  
  
Sin relación   
 
 
 
10. Durante la última semana, ¿cuánta dificultad 
le ha ocasionado su tratamiento  de la piel, por 
ejemplo, ocupándole tiempo o ensuciando o 
desordenando su casa?  Muchísimo  
Mucho  
Un poco  
Nada  
  
 
 
  
 
 
Sin relación   
 
 
 
 
Por favor verifique que ha contestado a TODAS las preguntas. Muchas gracias.  
 
 
 
 
La recopilación de esta información está utorizada bajo el Código de los Estados Unidos, número 
42 USC 285. La información que usted proporcione s erá usada principalmente para evaluar su 
salúd y calidad de vida. Esta informatción podria ser compartida con doctores e investigadores 
para fines de investigación o con monitores para garantizar que se mantengan las normas de 
seguridad.  El proveer esta i nformación es voluntario.  
77 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 19 APPENDIX G: DERMATOLOGY LIFE QUALITY  SCORING TOOL  
 
http://www.dermatology.org.uk/quality/dlqi/quality -dlqi-faqs.html   
The scoring of each answer is as follows:  
Very much  scored 3  
A lot  scored 2  
A little  scored 1  
Not at all  scored 0  
Not relevant  scored 0  
Question unanswered  scored 0  
Question 7: "prevented work or studying"  scored 3  
  
The DLQI is calculated by ad ding the score of each question. The maximum score is 30 and the 
minimum is 0. The higher the score, the more quality of life is impaired. The DLQI can be 
expressed as a percentage of the maximum possible score of 30 but we do not recommend this 
because th e "original" score is much easier to understand.  
  
Please Note:  The scores associated with the different answers should not be printed on the DLQI 
itself, as this might cause bias . 
Meaning of DLQI Scores  
0-1 = no effect at all on patient's life  
2-5 = smal l effect on patient's life  
6-10 = moderate effect on patient's life  
11-20 = very large effect on patient's life  
21-30 = extremely large effect on patient's life  
  
Detailed analysis of the DLQI  
  
The DLQI can also be analyzed  under six headings or dimens ions as follows:  
• Symptoms and feelings  Questions 1 and 2  Score maximum 6  
• Daily activities  Questions 3 and 4  Score maximum 6  
• Leisure  Questions 5 and 6  Score maximum 6  
• Work and School  Question 7  Score maximum 3  
78 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 • Personal relationships  Questions 8 and 9  Score maximum 6  
• Treatment  Question 10  Score maximum 3  
               
  
The scores for each of these sections can also be expressed as a percentage of either 6 or 3.  
Q. How do you handle missing data from DLQI?  
There is a very high success rate of accurate  completion of the DLQI. However, sometimes 
subjects do make mistakes.  
  
- If one question is left unanswered this is scored 0 and the scores are summed and expressed as 
usual out of a maximum of 30.  
- If two or more questions are left unanswered the quest ionnaire is not scored.  
- If question 7 is answered 'yes' this is scored 3 even if in the same question one of the other 
boxes is ticked.  
- If question 7 is answered 'no' or 'not relevant' but then either 'a lot' or 'a little' is ticked this is 
then score d 2 or 1.  
- If two or more response options are ticked for one question, the response option with the 
highest score should be recorded.  
- If there is a response between two tick boxes, the lower of the two score options should be 
recorded.  
- The DLQI can b e analyzed  by calculating the score for each of its six sub -scales (see above). 
When using sub -scales, if the answer to one question in a sub -scale is missing, that sub -scale 
should not be scored.  
 
 
Collection of this information is authorized under 42 USC  285. The primary use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and researchers for research purposes and to monitor personnel to assure 
that safety standards are maintained.  Submission of this information is voluntary.  
79 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 20 APPENDIX H: PUSTULAR DERMATOSIS CLINICAL ASSESSMENT SCALE  
 
PUSTULAR PASI CALCULATION  
PSORIASIS 
CHARACTERISTIC  RATING 
SCORE  HEAD  ARMS  TRUNK  
(including 
groin)  LEGS  
(including 
buttocks)  
Erythema/redness (E)  
Lt red, red, v red, deep red   
0 = None  
1 = Slight  
2 = Moderate  
3 = Severe  
4 = Very Severe   
    
Induration/thickness (I)  
0.25, 0.5, 1, 1.25mm   
    
Desquamation/scaling (D)  
Fine, coarse fine, coarse 
thick, v thick   
    
Pustul es (P)  
Few, scattered, dense, 
confluent   
    
SUM: E+I+ D+P   
    
Modifier  x 0.1  x 0.2  x 0.3  x 0.4  
Weighted plaque score  
 = sum x modifier      
% affected body surface area   
    
AREA SCORE  0 = None  
1 = 1 -9% 
2 = 10 -29% 
3 = 30 -49% 
4 = 50 -69% 
5 = 70 -89% 
6 = 90-100%   
    
SUBTOTAL = Weighted plaque score x 
Area score      
PUSTULAR PASI SCORE   
 
 
Signature                                             Printed Name                                                       Date  
 
80 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
  
MODIFIED PALMOPLANTAR  PASI CALCULAT ION  
PSORIASIS 
CHARACTERISTIC  RATING 
SCORE  RIGHT 
PALM  LEFT 
PALM  RIGHT 
SOLE  LEFT 
SOLE  
Erythema/redness (E)  
Lt red, red, v red, deep red   
0 = None  
1 = Slight  
2 = Moderate  
3 = Severe  
4 = Very Severe   
    
Pustules (P)  or Infiltration  
Few, scattered, dense, 
confluent   
    
Desquamation/scaling (D)  
Fine, coarse fine, coarse 
thick, v thick   
    
SUM: E+P +D  
    
Modifier  x 0.2  x 0.2  x 0.3  x 0.3  
Weighted plaque score  
 = sum x modifier      
% affected body surface area   
    
AREA SCORE  0 = None  
1 = 1 -9% 
2 = 10 -29% 
3 = 30 -49% 
4 = 50 -69% 
5 = 70 -89% 
6 = 90 -100%   
    
SUBTOTAL = Weighted plaque score x 
Area score      
PALMOPLANTAR  PASI SCORE   
 
 
 
Date of 
biopsy  Clinical 
findings  Location of 
biopsy  Affected/Unaffected  Reason for 
biopsy  
(D, R, D/R*)  
 
     
 
     
*D- Diagnostic; R -Research, D/R - Diagnostic/Research  
 
 
Signature                                             Printed Name                                                       Date  
 
81 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 TOTAL BODY SURFACE AREA INVOLVEMENT (TBSAI)  
 HEAD  ARMS  TRUNK  LEGS   
% affect ed area (plaques  & 
pustules )  
     
Body area: % affected area x 
modifier  x 0.1  x 0.2  x 0.3  x 0.4  TOTAL  
Subtotal       
 
 
PHYSICIAN GLOBAL ASSESSMENT (PGA)  
PGA RATING 
SCORE  Plaque PGA score  Pustule PGA score  Overall PGA score  
0 = Clear  
1 = Minimal  
2 = Mil d 
3 = Moderate  
4 = Severe  
5 = Very severe     
 
 
 
 
 
Signature                                         Printed Name                                                       Date  
 
82 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 PATIENT VISUAL ANALOGUE SCALES  
 
Skin pain due to skin disease: 0 (no pain) to 10  (worst imaginable pain)  
Joint pain due to skin disease: 0 (no pain) to 10 (worst imaginable pain)  
Itching: 0 (no itching) to 10 (worst imaginable itching)  
Overall disease severity: your assessment of the degree of severity of your disease  
 
 
 
 
   
 
 
SKIN PAIN 
(0-10) JOINT PAIN  
(0-10) PRURITUS  
(0-10) OVERALL DISEASE 
SEVERITY  
(0-10) 
    
 
 
 
 
 
 
 
 
Collection of this information is authorized under 42 USC 285. The primary use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and researchers for research purposes and to monitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary . Provider Signature                                         Printed Name                                                 Date  0  10  Skin Pain 
0  10 
  Pruritus  
0 10   Joint Pain   
Overall  
Disease  
Severity 0 10 
83 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 21 APPENDIX I: HEALTH ASSESSMENT QUESTIONNAIRE  
 
84 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
Collection of this information is authorized under 42 USC 285. The prima ry use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and researchers for research purposes and to monitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary.  
85 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 22 APPENDIX J: JOINT EXAM CLINICAL ASSESSMENT FORM  
 
Collection of this information is authorized under 42 USC 285. The primary use of the 
information you provide is to assess your health and quali ty of life. The information may be 
disclosed to clinicians and researchers for research purposes and to monitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary.  
86 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 23 APPENDIX K: REVIEW OF SYSTEMS  
 
MEDICAL HISTORY  
 
87 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 
 
Collection of this information is authorized under 42 USC 285. The primary use of the 
information you provide is to assess your health and quality of life. The information may be 
disclosed to clinicians and research ers for research purposes and to monitor personnel to assure 
that safety standards are maintained. Submission of this information is voluntary.  
88 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 24 APPENDIX L: CCR PROBLEM REPORT FORM  
 
CCR PROBLEM REPORT FORM  
NCI Protocol #:  Protocol Title:  
 
 Report version: (select one)  
____Initial Report  
____Revised Report  
____Follow -up  
Site Principal Investigator:  
   
Date of problem:     Location of problem: (e.g.,  patient’s home, 
doctor’s office ) 
 
 
Who identified the problem? (provi de role  (not name of person) : nurse, investigator, monitor, 
etc…)  
 
Brief Description of Subject  (if 
applicable)   
(Do NOT include personal 
identifiers)   Sex:  ___ Male  ___ Female  Age:   
 ___ Not applicable (more than subject is involved)  
 
Diagnosis under  study:   
Name the problem: (select all that apply)    
[  ] Adverse drug reaction   
[  ] Abnormal lab value   
[  ] Death   
[  ] Cardiac Arrest/ code  
[  ] Anaphylaxis  
89 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 [  ] Sepsis/Infection   
[  ] Blood product reaction  
[  ] Unanticipated surgery/procedure    
[  ] Change in status (e.g. increased level of care required)    
[  ] Allergy (non -medication)  
[  ] Fall  
[  ] Injury/Accident (not fall)  
[  ] Specimen collection issue   
[  ] Informed consent issue   
[  ] Ineligible for enrollment   
[  ] Breach of PI I  
[  ] Tests/procedures not performed on schedule  
[  ]  Other, brief  1 -2 word description: _________________________  
 
Detailed Description of the problem: (Include any relevant treatment, outcomes or pertinent 
history ): 
 
 
*Is this problem unexpected? (see the definition of unexpected in the protocol) )  __YES __NO  
Please explain:  
 
 *Is this problem related or possibly related to participation in the research?  __YES __NO  
Please explain:  
 
*Does the problem suggest the research places subjects or others at a greater risk of 
harm than was previously known or recognized?     __YES __NO      Please explain:  
 
 
Is this problem?  (select all that apply ) 
[  ] An Unanticipated Problem* that is:       [  ] Serious        [  ] Not Serious  
90 
Abbreviated Title:  Anakinra in pustular dermatoses   
Version Date: December 12 , 2018  
 
 [  ] A Protocol Deviation that is:                [  ] Serious        [  ] Not Serious  
[  ] Non -compliance  
*Note if the 3 criteria starred above are answered, “YES”, then this event is also a UP.  
Is the problem also (select one)   [  ] AE  [  ] Non-AE 
Have similar problems occurred on this protocol  at your site ? __YES __NO       
If “Yes”, how many?  ____      Please describe:  
Describe what steps you have already taken as a result of this problem:  
 
 
In addition to the NIH Intramural  IRB, this problem is also being reported to: (select all that 
apply ) 
[  ] Local IRB  
[  ] Study Sponso r 
[  ] Manufacturer : ____________________   
[  ] Institutional Biosafety Committee  
[  ] Data Safety Monitoring Board  
[  ] Other: _________________________ ___________   
[  ] None of the above , not applicable  
INVESTIGATOR’S SIGNATURE:   
 DATE:   
 
 